<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006096.pub4" GROUP_ID="IBD" ID="914005101908232087" MERGED_FROM="" MODIFIED="2017-11-14 13:29:41 +0000" MODIFIED_BY="John MacDonald" REVIEW_NO="147" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2017-11-14 13:29:41 +0000" MODIFIED_BY="John MacDonald">
<TITLE>Interventions for treating lymphocytic colitis</TITLE>
<CONTACT MODIFIED="2017-11-14 13:29:41 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="14344" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nilesh</FIRST_NAME><LAST_NAME>Chande</LAST_NAME><EMAIL_1>nilesh.chande@lhsc.on.ca</EMAIL_1><EMAIL_2>nchande2@uwo.ca</EMAIL_2><ADDRESS><ORGANISATION>London Health Sciences Centre - Victoria Hospital</ORGANISATION><ADDRESS_1>Room E6-321A</ADDRESS_1><ADDRESS_2>800 Commissioners Road East</ADDRESS_2><CITY>London</CITY><ZIP>N6A 5W9</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 667 6582</PHONE_1><FAX_1>+1 519 667 6820</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-11-14 13:29:41 +0000" MODIFIED_BY="John MacDonald"><PERSON ID="14344" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nilesh</FIRST_NAME><LAST_NAME>Chande</LAST_NAME><EMAIL_1>nilesh.chande@lhsc.on.ca</EMAIL_1><EMAIL_2>nchande2@uwo.ca</EMAIL_2><ADDRESS><ORGANISATION>London Health Sciences Centre - Victoria Hospital</ORGANISATION><ADDRESS_1>Room E6-321A</ADDRESS_1><ADDRESS_2>800 Commissioners Road East</ADDRESS_2><CITY>London</CITY><ZIP>N6A 5W9</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 667 6582</PHONE_1><FAX_1>+1 519 667 6820</FAX_1></ADDRESS></PERSON><PERSON ID="z1507071356127624814073879420824" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Noor</FIRST_NAME><LAST_NAME>Al Yatama</LAST_NAME><EMAIL_1>nalyatam@uwo.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="z1310221728361427434089677508791" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tania</FIRST_NAME><LAST_NAME>Bhanji</LAST_NAME><POSITION>Resident, PGY-1</POSITION><EMAIL_1>tania.bhanji@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="z1607251411590401623801479701474" ROLE="AUTHOR"><FIRST_NAME>Tran</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Nguyen</LAST_NAME><EMAIL_1>tran.nguyen@robartsinc.com</EMAIL_1><EMAIL_2>cochraneibdreviewgroup@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="8955" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John WD</FIRST_NAME><LAST_NAME>McDonald</LAST_NAME><SUFFIX>MD PhD FRCPC</SUFFIX><POSITION>Editor, IBD/FBD Group</POSITION><EMAIL_1>john.mcdonald@robartsinc.com</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 519 663 3533</PHONE_1><PHONE_2>+1 519 931 5280</PHONE_2><FAX_1>+1 519 663 3807</FAX_1><FAX_2>+1 519 931 5705</FAX_2></ADDRESS></PERSON><PERSON ID="9897" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>MacDonald</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>john.macdonald@robartsinc.com</EMAIL_1><EMAIL_2>jmacdon1@uwo.ca</EMAIL_2><URL>http://ibd.cochrane.org/</URL><ADDRESS><DEPARTMENT>Cochrane IBD Group</DEPARTMENT><ORGANISATION>Robarts Clinical Trials</ORGANISATION><ADDRESS_1>100 Dundas Street, Suite 200</ADDRESS_1><CITY>London</CITY><ZIP>N6A 5B6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+ 1 226 270 7868</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-11-13 17:23:31 -0500" MODIFIED_BY="John MacDonald">
<UP_TO_DATE>
<DATE DAY="11" MONTH="8" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="8" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-11-14 08:23:43 -0500" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-14 08:23:43 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="14" MONTH="11" YEAR="2017"/>
<DESCRIPTION>
<P>Correction of minor error in Figure 1 </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-11-14 08:27:36 -0500" MODIFIED_BY="John K MacDonald">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-11-14 08:23:12 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="11" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>Updated review with changes to conclusions and new authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-14 08:27:36 -0500" MODIFIED_BY="John K MacDonald">
<DATE DAY="11" MONTH="8" YEAR="2016"/>
<DESCRIPTION>
<P>New literature search performed on 11 August 2016. Two new studies were added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-05-06 11:53:51 -0400" MODIFIED_BY="John K MacDonald">
<DATE DAY="11" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment. See "other versions" for previously published versions of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-07-12 08:27:47 -0400" MODIFIED_BY="John K MacDonald">
<SUMMARY MODIFIED="2017-07-12 08:27:47 -0400" MODIFIED_BY="John K MacDonald">
<TITLE MODIFIED="2008-05-06 11:57:38 -0400" MODIFIED_BY="John K MacDonald">Treatments for lymphocytic colitis</TITLE>
<SUMMARY_BODY MODIFIED="2017-07-12 08:27:47 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>What is lymphocytic colitis?</B>
</P>
<P>Lymphocytic colitis is a type of microscopic colitis, a condition characterized by chronic non-bloody watery diarrhea. People with lymphocytic colitis have a normal appearing bowel when assessed by an endoscope (a camera used to look at the bowel) or an X-ray; but have microscopic (histological) inflammation of the bowel when assessed by a biopsy (a tissue sample taken during endoscopy). The cause of this disorder is unknown. This review is an update of a previously published Cochrane review.</P>
<P>
<B>What treatments have been tried for lymphocytic colitis?</B>
</P>
<P>Budesonide, mesalazine with or without cholestyramine, beclometasone dipropionate and bismuth subsalicylate (i.e. Pepto-Bismol®) have been tried as treatment for lymphocytic colitis. Budesonide is an immunosuppressive steroid drug that is quickly metabolized by the liver resulting in reduced steroid-related side-effects. It is taken by mouth. Beclometasone dipropionate is also a steroid drug. Steroid drugs are used to treat inflammation. Mesalazine (also known as 5-ASA) is an anti-inflammatory drug which is often taken by mouth. Cholestyramine is a drug that helps the body remove bile acids. Pepto-Bismol®, is an antacid medication used to treat temporary discomforts of the stomach and gastrointestinal tract.</P>
<P>
<B>What did the researchers investigate?</B>
</P>
<P>The researchers investigated whether these drugs improve the symptoms of lymphocytic colitis (e.g. diarrhea) or microscopic inflammation and whether any side effects result from treatment. The researchers searched the medical literature extensively up to 11 August 2016.</P>
<P>
<B>What did the researchers find?</B>
</P>
<P>Five studies including 149 participants were identified. These studies assessed budesonide versus placebo (e.g. a sugar pill), mesalazine versus mesalazine plus cholestyramine and beclometasone dipropionate versus mesalazine and Pepto-Bismol® versus placebo. The study which compared mesalazine to mesalazine plus cholestyramine and the study which compared beclometasone dipropionate to mesalazine were judged to be of low quality. The study which compared Pepto-Bismol® bismuth subsalicylate to a placebo was judged as low quality due to a very small sample size (5 participants) and limited data. The other three studies were judged to be high quality.</P>
<P>A pooled analysis of two studies (57 participants) showed that budesonide (9 mg/day for 6 to 8 weeks) was superior to placebo for improvement of diarrhea and improvement of microscopic inflammation of the bowel. Improvement in diarrhea was noted in 88% of budesonide participants compared to 38% of placebo participants. Improvement in microscopic inflammation was reported in 78% of budesonide participants compared to 33% of placebo participants. Forty-one participants were enrolled in the study that compared mesalazine (2.4. g/day) to mesalazine plus cholestyramine (4 g/day). Improvement in diarrhea was noted in 85% of participants in the mesalazine group compared to 86% of participants in the mesalazine plus cholestyramine group. Five patients were enrolled in the trial studying Pepto-Bismol® (nine 262 mg tablets daily for 8 weeks versus placebo). There were no differences in improvement of diarrhea or in improvement of microscopic inflammation of the bowel. Forty-six participants were enrolled in the trial studying beclometasone dipropionate (5 mg/day or 10 mg/day) versus mesalazine (2.4 g/day). Although participants receiving beclometasone dipropionate (84%) and mesalazine (86%) had improved diarrhea at 8 weeks, this improvement was not maintained at 12 months (26% and 20%, respectively). Side effects reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, excessive sweating and headache. Side effects reported in the mesalazine plus cholestyramine study included nausea and skin rash. Side effects in the beclometasone dipropionate trial included nausea, sleepiness and change of mood. No side effects were reported in the Pepto-Bismol® study.</P>
<P>Low quality evidence suggests that budesonide may be an effective therapy for the treatment of lymphocytic colitis. Low quality evidence also suggests that mesalazine with or without cholestyramine and beclometasone dipropionate may be effective for treatment of lymphocytic colitis. No conclusions can be made regarding bismuth subsalicylate due to the very small number of participants in the study. In the future, researchers should consider further large placebo-controlled trials of budesonide to confirm the suggested benefit and safety of this therapy. Bismuth subsalicylate, which has less potential for toxicity than budesonide, also warrants further study. The effectiveness and safety of mesalazine with or without cholestyramine, and beclometasone dipropionate need to be investigated in a large placebo-controlled studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-07-12 08:14:44 -0400" MODIFIED_BY="John K MacDonald">
<ABS_BACKGROUND MODIFIED="2016-01-06 12:01:33 -0500" MODIFIED_BY="Noor  Al Yatama">
<P>Lymphocytic colitis is a cause of chronic diarrhea. It is a subtype of microscopic colitis characterized by chronic, watery, non-bloody diarrhea and normal endoscopic and radiologic findings. The etiology of this disorder is unknown.Therapy is based mainly on case series and uncontrolled trials, or by extrapolation of data for treating collagenous colitis, a related disorder. This review is an update of a previously published Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-07-12 07:33:29 -0400" MODIFIED_BY="John K MacDonald">
<P>To evaluate the efficacy and safety of treatments for clinically active lymphocytic colitis. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-07-12 07:40:41 -0400" MODIFIED_BY="John K MacDonald">
<P>The MEDLINE, PUBMED and EMBASE databases were searched from inception to 11 August 2016 to identify relevant papers. Manual searches from the references of included studies and relevant review articles were performed.</P>
<P>Abstracts from major gastroenterological meetings were also searched to identify research submitted in abstract form only. The trial registry web site www.ClinicalTrials.gov was searched to identify registered but unpublished trials. Finally, the Cochrane Central Register of Controlled Trials and the Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Trials Register were searched for other studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-07-12 07:33:38 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized controlled trials assessing medical therapy for patients with biopsy-proven lymphocytic colitis were considered for inclusion</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-07-12 07:33:48 -0400" MODIFIED_BY="John K MacDonald">
<P>Data was independently extracted by at least two authors. Any disagreements were resolved by consensus. Data were analyzed on an intention-to-treat (ITT) basis. The primary outcome was clinical response as defined by the included studies. Secondary outcome measures included histological response as defined by the included studies, quality of life as measured by a validated instrument and the occurrence of adverse events. Risk ratios (RR) and 95% confidence intervals (CI) were calculated for dichotomous outcomes. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting the primary outcome and selected secondary outcomes was assessed using the GRADE criteria. Data were combined for analysis if they assessed the same treatments. Dichotomous data were combined using a pooled RR along with corresponding 95% CI. A fixed-effect model was used for the pooled analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-07-12 08:14:44 -0400" MODIFIED_BY="John K MacDonald">
<P>Five RCTs (149 participants) met the inclusion criteria. These studies assessed bismuth subsalicylate versus placebo, budesonide versus placebo, mesalazine versus mesalazine plus cholestyramine and beclometasone dipropionate versus mesalazine. The study which assessed mesalazine versus mesalazine plus cholestyramine and the study which assessed beclometasone dipropionate versus mesalazine were judged to be at high risk of bias due to lack of blinding. The study which compared bismuth subsalicylate versus us placebo was judged as low quality due to a very small sample size and limited data. The other 3 studies were judged to be at low risk of bias. Budesonide (9 mg/day for 6 to 8 weeks) was significantly more effective than placebo for induction of clinical and histological response. Clinical response was noted in 88% of budesonide patients compared to 38% of placebo patients (2 studies; 57 participants; RR 2.03, 95% CI 1.25 to 3.33; GRADE = low). Histological response was noted in 78% of budesonide patients compared to 33% of placebo patients (2 studies; 39 patients; RR 2.44, 95% CI 1.13 to 5.28; GRADE = low). Forty-one patients were enrolled in the study assessing mesalazine (2.4 g/day) versus mesalazine plus cholestyramine (4 g/day). Clinical response was noted in 85% of patients in the mesalazine group compared to 86% of patients in the mesalazine plus cholestyramine group (RR 0.99, 95% CI 0.77 to 1.28; GRADE = low). Five patients were enrolled in the trial studying bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks versus placebo). There were no differences in clinical (P=0.10) or histological responses (P=0.71) in patients treated with bismuth subsalicylate compared with placebo (GRADE = very low). Forty-six patients were enrolled in the trial studying beclometasone dipropionate (5 mg/day or 10 mg/day) versus mesalazine (2.4 g/day). There were no differences in clinical remission at 8 weeks (RR 0.97; 95% CI 0.75 to 1.24; GRADE = low) and 12 months of treatment (RR 1.29; 95% CI 0.40 to 4.18; GRADE = very low). Although patients receiving beclometasone dipropionate (84%) and mesalazine (86%) achieved clinical remission at 8 weeks, it was not maintained at 12 months (26% and 20%, respectively). Adverse events reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, hyperhidrosis and headache. Nausea and skin rash were reported as adverse events in the mesalazine study. Adverse events in the beclometasone dipropionate trial include nausea, sleepiness and change of mood. No adverse events were reported in the bismuth subsalicylate study.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-07-12 07:34:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Low quality evidence suggests that budesonide may be effective for the treatment of active lymphocytic colitis. This benefit needs to be confirmed by a large placebo -controlled trial. Low quality evidence also suggests that mesalazine with or without cholestyramine and beclometasone dipropionate may be effective for the treatment of lymphocytic colitis, however this needs to be confirmed by large placebo-controlled studies. No conclusions can be made regarding bismuth subsalicylate due to the very small number of patients in the study, Further trials studying interventions for lymphocytic colitis are warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-07-12 08:17:18 -0400" MODIFIED_BY="John K MacDonald">
<BACKGROUND MODIFIED="2017-07-12 07:36:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Lymphocytic colitis is a cause of chronic watery diarrhea. It is related to collagenous colitis, and together these two disorders are more broadly categorized as "microscopic colitis", with normal radiologic and endoscopic findings, but typical histological features on biopsies. Population-based studies in Europe have reported an annual incidence of collagenous colitis ranging from 0.6 to 5.2 per 100,000 persons and a prevalence of 10 to 15.7 per 100,000 population, while lymphocytic colitis has a reported annual incidence ranging from 3.1 to 4.4 per 100,000 persons and a prevalence of 14.2 per 100,000 population (<LINK REF="REF-Agnarsdottir-2002" TYPE="REFERENCE">Agnarsdottir 2002</LINK>; <LINK REF="REF-Bohr-1995" TYPE="REFERENCE">Bohr 1995</LINK>; <LINK REF="REF-Fernandez-1999" TYPE="REFERENCE">Fernandez 1999</LINK>; <LINK REF="REF-Olesen-2004a" TYPE="REFERENCE">Olesen 2004a</LINK>; <LINK REF="REF-Raclot-1994" TYPE="REFERENCE">Raclot 1994</LINK>). A population based study in the United States reported an annual incidence of collagenous and lymphocytic colitis of 5.1 and 9.8 per 100,000 persons and a prevalence of 36 and 64 per 100,000 population respectively (<LINK REF="REF-Pardi-2004a" TYPE="REFERENCE">Pardi 2004a</LINK>).</P>
<P>Lymphocytic colitis is distinguished from collagenous colitis by the presence of an increased number of intraepithelial lymphocytes (&gt;20 per 100 epithelial cells) and the absence of a markedly thickened subepithelial collagen band. The etiology and pathogenesis of lymphocytic colitis are uncertain, although links to autoimmune disorders and the use of nonsteroidal anti-inflammatory drugs have been suggested (<LINK REF="STD-Loftus-2003" TYPE="STUDY">Loftus 2003</LINK>; <LINK REF="REF-Pardi-2004b" TYPE="REFERENCE">Pardi 2004b</LINK>; <LINK REF="REF-Schiller-2004" TYPE="REFERENCE">Schiller 2004</LINK>). Treatment has been mainly based on anecdotal evidence, and includes dietary modification, antidiarrheals, bulking agents, bile acid binding agents, spasmolytics, antibiotics, bismuth subsalicylate, sulfasalazine/other 5-ASA products, traditional corticosteroids, budesonide, azathioprine/6-mercaptopurine, cyclosporine, probiotics and surgery (See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Various therapies have been evaluated in randomized controlled studies in patients with collagenous colitis (<LINK REF="REF-Chande-2008a" TYPE="REFERENCE">Chande 2008a</LINK>), but it is not known if the results of these studies can be extrapolated to treating patients with lymphocytic colitis. Treatments for lymphocytic colitis that have been investigated in randomized controlled trials include budesonide (<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>; <LINK REF="STD-NCT00184171" TYPE="STUDY">NCT00184171</LINK>; <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>), mesalazine with or without cholestyramine (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>), bismuth subsalicylate (<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-NCT00184171" TYPE="STUDY">NCT00184171</LINK>) and beclometasone dipropionate (<LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>). This systematic review is an update of a previously published Cochrane review (<LINK REF="REF-Chande-2007" TYPE="REFERENCE">Chande 2007</LINK>; <LINK REF="REF-Chande-2008b" TYPE="REFERENCE">Chande 2008b</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness of therapies for clinically active lymphocytic colitis studied in randomized trials.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-07-12 08:09:05 -0400" MODIFIED_BY="John K MacDonald">
<SELECTION_CRITERIA MODIFIED="2017-07-12 07:36:21 -0400" MODIFIED_BY="John K MacDonald">
<CRIT_STUDIES MODIFIED="2017-07-12 07:36:19 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized controlled trials were considered for inclusion. Studies published as abstracts were only included if the authors could be contacted to obtain further information.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-07-12 07:36:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Patients with biopsy-proven clinically active lymphocytic colitis without other significant radiologic or endoscopic findings were considered for inclusion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-07-12 07:36:20 -0400" MODIFIED_BY="John K MacDonald">
<P>All types of therapy were eligible for inclusion.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-07-12 07:36:21 -0400" MODIFIED_BY="John K MacDonald">
<P>The primary outcome measure was clinical response as defined by the included studies (e.g. decreased stool frequency or stool weight or both). Secondary outcome measures included histological response as defined by the included studies, quality of life as measured by a validated instrument and the occurrence of adverse events.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-07-12 07:36:25 -0400" MODIFIED_BY="John K MacDonald">
<ELECTRONIC_SEARCHES MODIFIED="2017-07-12 07:36:24 -0400" MODIFIED_BY="John K MacDonald">
<P>EMBASE, MEDLINE, the Cochrane Library (CENTRAL) and the Cochrane IBD Group Specialized Register were searched from inception to 11 August 2016. The search strategies are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. Conference abstracts from Digestive Disease Week and the United European Gastroenterology Week were also searched to identify abstract publications.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-07-12 07:36:25 -0400" MODIFIED_BY="John K MacDonald">
<P>We searched reference lists from potentially relevant papers to identify additional studies that may have been missed using the computer-assisted search strategy. The trial database clinicaltrials.gov was also searched to identify studies that may have not been reported.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-07-12 08:09:05 -0400" MODIFIED_BY="John K MacDonald">
<P>Study Selection:<BR/>At least two authors (NY, TMN or TB) Each author independently reviewed potentially relevant studies to determine eligibility based on the criteria specified above. Studies published in abstract form were only included if the authors could be contacted to clarify details about the protocol and results. Any disagreement was resolved by consensus.</P>
<P>Data Collection:<BR/>A data extraction form was developed and used to extract information on results of included studies. A minimum of two authors (NY, TMN or TB) independently extracted the data, any disagreement among authors was resolved by consensus.</P>
<P>Statistical Analysis:<BR/>Data was analyzed using Review Manager (RevMan 5.3.5). If cross-over studies are identified in future updates, only data from the first arm will be included. All data were analyzed on an intention-to-treat basis. Data were extracted and converted into two by two tables (treatment versus comparator and clinical response versus no response; treatment versus comparator and histological response versus no response). For therapies assessed in one trial only, P values were derived using the Chi<SUP>2</SUP> test. If in the future, therapies are assessed in more than one trial, summary test statistics will be derived by calculating the risk ratio (RR) and corresponding 95% confidence interval (95% CI). The authors of each paper set the definitions of clinical and histological response and the data were combined for analysis only if these definitions were sufficiently similar (determined by consensus). The presence of heterogeneity among studies was assessed using the Chi<SUP>2</SUP> test (a P value of 0.10 will be regarded as statistically significant). If statistically significant heterogeneity is identified the RR and 95% CI will be calculated using a random-effects model.</P>
<P>Quality Assessment:<BR/>
</P>
<P>At least two authors (NY, TMN or TB) independently assessed the methodological quality of included studies using the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Factors assessed included:</P>
<OL>
<LI>Random sequence generation;</LI>
<LI>Allocation concealment;</LI>
<LI>Blinding of participants, outcome assessors and investigators;</LI>
<LI>Incomplete outcome reporting (i.e. there was an acceptable method of dealing with attrition);</LI>
<LI>Selective outcome reporting (i.e. all outcomes described in the methods were included in the analysis);</LI>
<LI>Other potential sources of bias.</LI>
</OL>
<P>A judgement of 'Yes' indicates low risk of bias, 'No' indicates high risk of bias, and 'Unclear' indicates unclear or unknown risk of bias. Disagreements were resolved by consensus. Study authors were contacted when insufficient information was provided to determine risk of bias.</P>
<P>We used the GRADE criteria to assess the overall quality of the evidence supporting the primary outcome and selected secondary outcomes (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). The overall quality of evidence can be graded as:</P>
<P>1. High: Further research is very unlikely to change our confidence in the estimate of effect;</P>
<P>2. Moderate: Further research is likely to have an impact on our confidence in the estimate of effect and may change the estimate;</P>
<P>3. Low: Further research is very likely to have an important impact on our confidence on the estimate of effect and is likely to change the estimate; or</P>
<P>4. Very low: Any estimate of effect is very uncertain.</P>
<P>The overall quality of evidence can be downgraded by one (serious concern) or two levels (very serious concern) for the following reasons: risk of bias, inconsistency (e.g. unexplained heterogeneity), indirectness (e.g. indirect population, intervention, control or outcomes), publication bias, and imprecision (e.g. sparse data, few events). Imprecision was determined principally by a small number of studies for a comparison (two or fewer studies) and fewer than 100 events for that comparison. We used the GRADEproGDT software to produce Summary of Findings Tables.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-07-12 08:17:18 -0400" MODIFIED_BY="John K MacDonald">
<STUDY_DESCRIPTION MODIFIED="2017-07-12 07:36:54 -0400" MODIFIED_BY="John K MacDonald">
<P>A literature search conducted on August 11, 2016 identified 333 records. Two additional studies were identified through searching of conference and other sources. After duplicates were removed, a total of 248 trials remained for review of titles and abstracts. Twenty-seven studies were selected for full text review (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Twenty studies were excluded (See: <A HREF="http://archie.cochrane.org/sections/documents/view?document=262299092210574242&amp;format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES">Characteristics of excluded studies</A>). Seven reports of 5 studies (n = 149 patients) met the pre-defined inclusion criteria and were included in the review (<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>; <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>; <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>). A search of clinical trials.gov identified two ongoing randomized trials (<LINK REF="STD-NCT00184171" TYPE="STUDY">NCT00184171</LINK>; <LINK REF="STD-NCT01209208" TYPE="STUDY">NCT01209208</LINK>). The <LINK REF="STD-NCT00184171" TYPE="STUDY">NCT00184171</LINK> study plans to assess the treatment of lymphocytic colitis with budesonide (9 mg/day), bismuth or fiber. The <LINK REF="STD-NCT01209208" TYPE="STUDY">NCT01209208</LINK> plans to assess treatment of lymphocytic colitis with budesonide (9 mg/day), mesalazine (3 g/day) or placebo. The results of these ongoing studies will be included in future updates of this review when the study results become available.</P>
<P>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>, which was published in abstract form only, was a randomized, double-blind, placebo-controlled trial that compared bismuth subsalicylate to placebo in 14 patients (11 females: 3 males; age range 35 to 78 years) with microscopic colitis. Of these, five patients had lymphocytic colitis and nine had collagenous colitis. Patients were treated with bismuth subsalicylate (n = 3; nine 262 mg chewable tablets daily in 3 divided doses) or an identical placebo (n = 2) for 8 weeks. Each patient underwent 48-hour stool collection prior to treatment and on the last two days of treatment stool weight and consistency were evaluated using standardized criteria. All patients underwent flexible sigmoidoscopy with standardized biopsy prior to entry and after treatment. Patients were not to take antibiotics or anti-inflammatory agents for a minimum of 6 weeks, and antidiarrheals for minimum of 2 weeks prior to entry. Clinically active lymphocytic colitis was defined as at least eight weeks of non-bloody watery diarrhea with normal radiologic and endoscopic findings. Lymphocytic colitis was confirmed by histopathology consisting of excess mononuclear inflammatory cells in the lamina propria and surface epithelium without significant neutrophilic or eosinophilic inflammation, numerous crypt abscesses, or granuloma; the absence of a thickened subepithelial collagen band; and no other evidence of Crohn's disease. The histological score ranged from 0 to 10 and was based on the following five parameters: surface epithelium (microulceration, cell flattening and mucin depletion - scored 0 to 2); crypts; lamina propria cellularity; numbers of intraepithelial lymphocytes within the surface epithelium and the number of intra epithelial lymphocytes within the crypt epithelium. A clinical response was defined as the improvement of diarrhea to the passage of two or less formed or semi formed stools per day. A histological response was defined as a reduction in the histopathology score by greater than 50%. Adverse events were also documented.</P>
<P>
<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK> was a randomized, open-label trial comparing mesalazine to mesalazine plus cholestyramine for the treatment of patients with active microscopic colitis. The study included 23 patients with collagenous colitis and 41 with lymphocytic colitis. Patients were randomized via a computer generated list to oral mesalazine 800 mg three times daily (n = 20) or oral mesalazine 800 mg three times daily plus cholestyramine 4 g once daily (n = 21) for 6 months of treatment. The diagnosis of lymphocytic colitis was based on clinical and histological criteria. Clinically active lymphocytic colitis was defined as chronic or recurrent non-bloody diarrhea. Histological criteria included increased chronic inflammatory infiltrate (plasma cells, lymphocytes, eosinophils) in the lamina propria; increased number of intraepithelial lymphocytes, damage to surface epithelium, with flattening of epithelial cells or epithelial loss or both and detachment and minimal crypt architecture distortion. In addition, the number of intraepithelial lymphocytes had to be greater than 20 per 100 epithelial cells in the absence of a thickened subepithelial collagen layer to diagnose lymphocytic colitis. Patients with a clear correlation between symptoms and consumption of drugs (e.g. nonsteroidal anti-inflammatory drugs (NSAIDS), ticlopidine, or proton pump inhibitors) were excluded. All patients underwent a colonoscopy pre-treatment and 20 patients also underwent a colonoscopy at the end of 6 months. Outcomes included complete and partial clinical response and histological response. Complete response was defined as complete resolution of diarrhea. Partial clinical response was defined as improvement but not resolution of diarrhea. Histological response was defined as normalization of histologic pattern at the end of six months. Adverse events were also reported.</P>
<P>
<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK> was a randomized, double-blind, placebo-controlled trial that compared oral budesonide to placebo in patients with lymphocytic colitis. Forty-two patients (28 females;14 males; median age 61) with lymphocytic colitis were randomized in a 1:1 ratio via a centralized randomization list in blocks of four to receive oral budesonide (9 mg/day, n = 21) or placebo (n = 20) for 6 weeks of treatment. Non-responders at week six were treated with open-label budesonide (9 mg/day) for an additional 6 weeks. Clinically active lymphocytic colitis was defined as more than three watery or loose stools per day on average, for at least 4 weeks. The diagnosis of lymphocytic colitis was based on histology and confirmed by the central pathologist. The number of intraepithelial lymphocytes had to be greater than 20/100 epithelial cells, with inflammation of the lamina propria. The primary outcome measure was clinical remission at 6 weeks which was defined as no more than 3 non-watery stools per day on average, and a reduction in more than stool compared with screening. Complete colonoscopy including histology was assessed at entry and after 6 weeks, and was used to determine rates of histological remission and histological response. Histological remission was defined as a reduction in the number of intraepithelial lymphocytes to less than 20/100 epithelial cells, plus a reduction in lamina propria inflammation. Histological response was defined as a greater than 50% reduction in the number of intraepithelial lymphocytes compared to baseline or a reduction in lamina propria inflammation or both. Other outcome measures included clinical remission from lymphocytic colitis after 3 weeks, quality of life, which was assessed at entry and after 6 weeks with the validated SF-36 instrument (a 36 item questionnaire measuring both physical and mental components of quality of life), and the occurrence of adverse events.</P>
<P>
<LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> was a double-blind, randomized controlled trial comparing controlled ileal-release budesonide to placebo for the treatment of patients with diarrhea and microscopically confirmed lymphocytic colitis (the criteria were not described). Patients with possible drug-induced lymphocytic colitis were excluded, unless symptoms persisted despite discontinuation of the offending medication. The study included 15 patients who were randomized to receive either 9 mg/day of budesonide (3 x 3 mg; n = 11) or three placebo capsules (n = 4). Symptoms were self-recorded daily then averaged for each week of the study. The primary outcome was global assessment of improvement in diarrhea as assessed by the patient. This was defined as at least a 50% improvement in the frequency of bowel movements in at least three of the last four weeks of the study, compared to baseline. Clinical histologic features were graded on a four-point scale which accounted for features such as intraepithelial lymphocyte infiltration and lamina propria cellularity. Colon biopsies were taken before study entry, and follow-up sigmoidoscopy and biopsy was requested from each subject at the end of the study. No definitions were provided for either complete or partial clinical remission, or histologic remission. As such, all results were described in terms of either improvement or worsening of the patient's condition. In our analysis, we defined clinical response as an improvement in global assessment score and histologic response as an improvement in the histologic score. Secondary outcomes included improvement in number of bowel movements per day, consistency of stool, abdominal discomfort, histology and adverse events.</P>
<P>
<LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>, which was published in abstract form only, was a randomized, open-label trial comparing beclometasone dipropionate to mesalazine for the treatment of patients with lymphocytic colitis. The study included 46 patients with lymphocytic colitis. The diagnosis of lymphocytic colitis was based on clinical and histological criteria. Clinically active lymphocytic colitis was defined as greater than 3 watery or loose stools per day on average per week and a history of diarrhea lasting for more than four weeks. Histologic criteria included a complete colonoscopy with colonic biopsies within four weeks of entry, and a histologically confirmed diagnosis of active lymphocytic colitis. Patients were randomized to receive beclometasone dipropionate 5 mg/day (n = 18), beclometasone dipropionate 10 mg/day (n = 13) or mesalazine 2.4 g/day (n = 15) for 8 weeks. Outcomes included clinical remission at 8 weeks, defined as less than or equal to 3 soft or solid stools per day during the last week of treatment, and relapse at 6 and 12 months after treatment, defined as greater than three stools per day on four or more consecutive days.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-07-12 07:37:06 -0400" MODIFIED_BY="John K MacDonald">
<P>The overall results of the risk of bias analysis are reported in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2017-07-12 07:37:04 -0400" MODIFIED_BY="John K MacDonald">
<P>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> reported that randomization was achieved by pulling pieces of paper out of a sealed box. Based on this information we decided to rate random sequence generation as low risk. The other four studies reported the use of computer-generated randomization and these studies were also rated as low risk of bias (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>; <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>; <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>).</P>
<P>Two studies did not describe methods used for allocation concealment and were rated as unclear for this item (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>). Two studies employed a centralized randomization scheme and were rated as low risk of bias for allocation concealment (<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>; <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>). The <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> used opaque sealed envelopes to conceal allocation and therefore this was rated as low risk of bias for this item.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-07-12 07:37:06 -0400" MODIFIED_BY="John K MacDonald">
<P>Two studies were open-label and were rated as high risk of bias for blinding (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>). Both the caregivers and data analysts were blinded for the <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK> study. Two studies were described as double-blind and utilized an identical placebo and thus were rated as low risk of bias for blinding (<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>). The <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> study was described as double-blind. However, an identical placebo was not available from the sponsor at the time of the study. All research personal including the pathologist were blinded to treatment assignment. Patients did not know treatment assignment unless they discovered what budesonide was supposed to look like. The authors did not formally assess whether patients knew which treatment they received. The <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> study was rated as unclear risk of bias for blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-05-30 13:04:43 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Three studies reported that there were no drop outs (<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>; <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>; <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>). These studies were rated as low risk of bias for incomplete outcome data. One patient dropped out of the <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> study, which was rated as low risk of bias for incomplete outcome data. Dropouts were balanced across treatment groups in the <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK> study and this study was rated as low risk of bias for incomplete outcome data. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-07-12 07:37:06 -0400" MODIFIED_BY="John K MacDonald">
<P>All of the included studies were rated as low risk of bias for selective outcome reporting as all expected outcomes were reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-04-02 12:12:46 -0400" MODIFIED_BY="John K MacDonald">
<P>All of the included studies were rated as low risk of bias for other potential sources of bias. These studies appeared to be free of other potential sources of bias. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-07-12 08:17:18 -0400" MODIFIED_BY="John K MacDonald">
<P>
<B>Bismuth subsalicylate versus placebo </B>
</P>
<P>
<B>Clinical response</B>
</P>
<P>In the <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> study, all 3 patients in the bismuth subsalicylate group achieved a clinical response after 8 weeks of treatment, while those 2 patients assigned to placebo did not (RR 5.25, 95% CI 0.41 to 67.73). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (allocation concealment) and very serious imprecision (3 events; See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Histological response</B>
</P>
<P>In <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>, 2 of 3 patients in the bismuth subsalicylate group achieved a histological response after 8 weeks of treatment, compared to 1 of the 2 patients treated with placebo (RR 1.33, 95% CI 0.27 to 6.61). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to unclear risk of bias (allocation concealment) and very serious imprecision (3 events; See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>
<B>Quality of life</B>
</P>
<P>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> did not report on quality of life as an outcome measure.</P>
<P>
<B>Adverse events</B>
</P>
<P>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK> reported no adverse events in either the bismuth subsalicylate or placebo groups.</P>
<P>
<B>Budesonide versus placebo</B>
</P>
<P>
<B>Clinical response</B>
</P>
<P>In <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>, 18 of 21 patients in the budesonide group achieved a clinical response after 6 weeks of treatment, compared to 10 of 21 patients in the placebo group (RR 1.80, 95% CI 1.11 to 2.91). The number needed to treat to achieve a clinical response with budesonide was 3 patients.</P>
<P>In <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>, 10 of 11 patients in the budesonide group achieved a clinical response after 8 weeks of treatment, compared to 1 of 4 patients in the placebo group (RR 3.64, 95% CI 0.66 to 20.06).</P>
<P>The pooled analysis for clinical response showed a statistically significant benefit for budesonide over placebo. Clinical response was noted in 88% of budesonide patients compared to 38% of placebo patients (2 studies; 56 participants; RR 2.03, 95% CI 1.25 to 3.33; I<SUP>2</SUP> = 0%). The number needed to treat to achieve a clinical response with budesonide was two. A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to unclear risk of bias for blinding and sparse data (39 events; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Histological response</B>
</P>
<P>In <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>, 11 of 15 patients in the budesonide group who underwent a follow-up colonoscopy achieved a histological response after 6 weeks of treatment, compared to 4 of 13 patients in the placebo group who underwent a follow-up colonoscopy (RR 2.81, 95% CI 1.00 to 5.69). The number needed to treat to achieve a histological response with budesonide was 3 patients.<BR/>
</P>
<P>In <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK>, 7 of 8 patients in the budesonide group who underwent follow-up sigmoidoscopy achieved a histological response after 8 weeks of treatment, compared to 1 of 3 patients ) in the placebo group (RR 2.63 95% CI 0.52 to 13.29).</P>
<P>The pooled analysis for histological response showed a statistically significant benefit for budesonide over placebo. Histological response was noted in 78% of budesonide patients compared to 33% of placebo patients (2 studies; 39 participants; RR 2.44, 95% CI 1.13 to 5.28; I<SUP>2</SUP> = 0%). The number needed to treat to achieve a histological response with budesonide was three. A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very sparse data (23 events; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>
<B>Quality of life</B>
</P>
<P>SF-36 scores at baseline were reduced compared to normal values for both the physical and mental domains. In the budesonide group, the mean physical sum score increased from 42.0 at baseline to 49.7 after 6 weeks of treatment, while the mean mental sum score was unchanged, with a value of 46.5 at baseline and 46.9 after 6 weeks (<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>). In the placebo group, the mean physical sum score increased from 44.1 at baseline to 48.0 after 6 weeks of treatment, while the mean mental sum score was unchanged, with a value of 49.0 at baseline and 49.1 after 6 weeks (<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>).</P>
<P>
<B>Adverse events</B>
</P>
<P>In <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK>, 6 adverse events occurred in 2 patients (10%) in the budesonide group, compared to 9 adverse events in 3 patients (15%) in the placebo group (RR 0.63, 95% CI 0.12 to 3.41). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to very sparse data (5 events; See <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). All adverse events were graded as mild or moderate in intensity. The most common adverse event were headaches. One patient in the budesonide group withdrew due to adverse events (nausea and headache) and one patient in the placebo group withdrew due to adverse events. Serious adverse events were reported in two placebo patients (nausea, abdominal pain, and hyperhidrosis in one patient; and headache, neck pain, and abdominal discomfort in the other patient).</P>
<P>
<LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> reported no adverse events in either budesonide or placebo treatment groups.</P>
<P>
<B>Mesalazine versus mesalazine + cholestyramine</B>
</P>
<P>
<B>Clinical response</B>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, 17 of 20 patients in the mesalazine alone group achieved a clinical response after 6 months of treatment, compared to 18 of 21 patients in the mesalazine + cholestyramine group (RR 0.99; 95% CI 0.77 to 1.28). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to high risk of bias (blinding), unclear allocation concealment and sparse data (35 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Histological response</B>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, all patients with lymphocytic colitis who had a clinical response showed a normalization of histological features, specifically normalization of intraepithelial lymphocytes. Seventeen of 20 patients in the mesalazine group had a histological response compared to 18 of 21 patients in the combined mesalazine + cholestyramine group (RR 0.99; 95% CI 0.77 to 1.28). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to high risk of bias (blinding), unclear allocation concealment and sparse data (35 events; See <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<P>
<B>Quality of life</B>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, quality of life was not reported as an outcome measure.</P>
<P>
<B>Adverse events</B>
</P>
<P>In <LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK>, 2 of 21 patients (10%) in the mesalazine + cholestyramine group reported nausea as an adverse event. This was considered a mild event and did not lead to study withdrawal. No events were reported in the mesalazine alone group.</P>
<P>
<B>Beclometasone dipropionate versus mesalazine</B>
</P>
<P>
<B>Clinical response</B>
</P>
<P>In <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK>, 15 of 18 patients in the 5 mg/day beclometasone dipropionate group achieved a clinical remission after 8 weeks of treatment, compared to 11 of 13 in the 10 mg/day beclometasone dipropionate group, and 13 of 15 in the mesalazine group. There was no statistically significant difference in the proportion of patients who achieved clinical remission. Eighty-four per cent (26/31) of patients in the beclometasone dipropionate group achieved remission compared to 86% (13/15) of mesalazine patients (RR 0.97, 95% CI 0.75 to 1.29). A GRADE analysis rated the overall quality of the evidence supporting this outcome as low due to high risk of bias (blinding) and sparse data (39 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>At 12 months, 5 of 18 patients (28%; 95% CI 12% to 51%) in the beclometasone dipropionate group maintained clinical remission compared to 3 of 13 patients (23%; 95% CI 8% to 50%) in the 10 mg/day beclometasone dipropionate group and 3 of 15 patients (20%; 95% CI 7% - 45%) in the mesalazine group. There was no statistically significant difference in the proportion of patients who maintained clinical remission. Twenty-six per cent (8/31) of patients in the beclometasone dipropionate group maintained remission at 12 months compared to 20% (3/15) of mesalazine patients (RR 1.29, 95% CI 0.40 to 4.18). A GRADE analysis rated the overall quality of the evidence supporting this outcome as very low due to high risk of bias (blinding) and very sparse data (11 events; See <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<P>
<B>Histological response</B>
</P>
<P>
<LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK> did not report on histological response as an outcome measure.</P>
<P>
<B>Quality of life</B>
</P>
<P>
<LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK> did not report on quality of life as an outcome measure.</P>
<P>
<B>Adverse events</B>
</P>
<P>In the <LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK> study, 3 of 46 patients discontinued treatment prematurely because of adverse events; one from each of the three groups. Adverse events reported in the beclometasone dipropionate group were nausea,sleepiness and change of mood in the 5 mg/day and 10 mg/day groups, respectively. In the mesalazine group, one patient discontinued treatment due to a skin rash.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-07-12 07:38:13 -0400" MODIFIED_BY="John K MacDonald">
<P>Lymphocytic colitis is a cause of chronic diarrhea. It is related to collagenous colitis, and together these two disorders fall under the more general term 'microscopic colitis'. In the past, most research has focused on the therapy of collagenous colitis, and as a result, clinicians treating patients with lymphocytic colitis have relied on the results of uncontrolled trials, case series, and the extrapolation of data for treating collagenous colitis. However, there are currently five RCTs that exist for the treatment of lymphocytic colitis.</P>
<P>The results of <LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK> and <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> provide low quality evidence suggesting that budesonide may be effective at inducing both clinical and histological responses in patients with active lymphocytic colitis. Budesonide also appears to be well-tolerated in these patients. However, both trials were small in size (<LINK REF="STD-Miehlke-2009" TYPE="STUDY">Miehlke 2009</LINK> with 42 patients, <LINK REF="STD-Pardi-2009" TYPE="STUDY">Pardi 2009</LINK> with 15 patients) and the results should be interpreted with caution. In comparison, three studies examined the use of budesonide as therapy for active collagenous colitis, demonstrating both a clinical and histological benefit after six to eight weeks of treatment with 9 mg daily or in a tapering schedule (<LINK REF="REF-Baert-2002" TYPE="REFERENCE">Baert 2002</LINK>; <LINK REF="REF-Bonderup-2003" TYPE="REFERENCE">Bonderup 2003</LINK>; <LINK REF="REF-Miehlke-2002" TYPE="REFERENCE">Miehlke 2002</LINK>). Additionally, two studies demonstrated that budesonide is effective at maintaining clinical and histological responses in collagenous colitis over a period of six months (<LINK REF="REF-Bonderup-2007" TYPE="REFERENCE">Bonderup 2007</LINK>; <LINK REF="REF-Miehlke-2007b" TYPE="REFERENCE">Miehlke 2007b</LINK>). It is conceivable that budesonide would be similarly effective in patients with lymphocytic colitis, but this needs to be proven in larger randomized placebo-controlled trials.</P>
<P>
<LINK REF="STD-Calabrese-2007" TYPE="STUDY">Calabrese 2007</LINK> included 41 patients with lymphocytic colitis in a trial of mesalazine versus mesalazine plus cholestyramine. Clinical response was achieved in 85% of patients who received mesalazine compared to 86% of patients who received mesalazine plus cholestyramine (P = 0.95). The addition of cholestyramine to the treatment regimen did not provide any additional benefit for patients with lymphocytic colitis. Both treatments appeared to be well-tolerated. The results of this study provide low quality evidence suggesting that mesalazine (800 mg three times daily) with or without cholestyramine may be effective for treatment of lymphocytic colitis. Additionally, 23 patients with collagenous colitis enrolled in the same trial responded similarly to these treatments. However, these results should be interpreted with caution due to the small number of patients enrolled, the lack of blinding and no placebo control. Some of the measured effect in both groups may have been due to spontaneous improvement of the disease. The potential benefits and harms of mesalazine with or without cholestyramine needs to be confirmed by a large placebo-controlled study.<BR/>
<BR/>
<LINK REF="STD-Latella-2010" TYPE="STUDY">Latella 2010</LINK> assessed the 12-month clinical outcomes of 46 patients with lymphocytic colitis who were randomized to beclometasone dipropionate at doses of 5 mg/day or 10 mg/day or mesalazine at a dose of 2.4 g/day. Clinical remission was achieved in 84% of patients in the beclometasone dipropionate group and 86% of the mesalazine group at 8 weeks (P = 0.80). This study provides low quality evidence suggesting that beclometasone dipropionate and mesalazine may be effective in achieving clinical remission. However, at 12 months only 26% of patients in the beclometasone dipropionate group and 20% in the mesalazine group maintained clinical remission (P = 0.67). This study provides very low quality evidence suggesting that these interventions may not be effective in maintaining remission. Moreover, this trial should be interpreted with caution as there was a small number of patients enrolled, and there was a lack of blinding and no placebo control. Both treatments appear to be well tolerated. The efficacy and safety of beclometasone dipropionate and mesalazine in achieving and maintaining remission needs to be assessed in a large placebo-controlled trial.<BR/>
<LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>, which studied bismuth subsalicylate therapy for lymphocytic colitis included only five patients with this diagnosis. Although all three patients receiving active drug experienced clinical improvement compared to none of the placebo patients there were no statistically significant differences in clinical or histological response. While these findings are of interest and provide very low quality evidence suggesting that this medication may be effective for treating lymphocytic colitis, no conclusions can be made from such a small number of patients. Additionally, nine patients with collagenous colitis enrolled in this study demonstrated a clinical and histological benefit with bismuth subsalicylate over placebo.</P>
<P>Although lymphocytic colitis and collagenous colitis are similar disorders, it has not been proven that therapies effective for one disorder will also be effective for the other. Epidemiologically, these two disorders are quite similar. Although most early reports of patients with microscopic colitis described collagenous colitis rather than lymphocytic colitis (<LINK REF="REF-Zins-1995" TYPE="REFERENCE">Zins 1995</LINK>), recent population-based studies suggest similar frequencies for these disorders (<LINK REF="REF-Fernandez-1999" TYPE="REFERENCE">Fernandez 1999</LINK>; <LINK REF="REF-Olesen-2004a" TYPE="REFERENCE">Olesen 2004a</LINK>). Both disorders are more common in women than in men, although the relative frequency of collagenous colitis in women is greater than that for lymphocytic colitis (<LINK REF="REF-Chande-2005" TYPE="REFERENCE">Chande 2005</LINK>; <LINK REF="REF-Fernandez-1999" TYPE="REFERENCE">Fernandez 1999</LINK>; <LINK REF="REF-Olesen-2004a" TYPE="REFERENCE">Olesen 2004a</LINK>). The mean age at diagnosis is in the sixth or seventh decade (<LINK REF="REF-Agnarsdottir-2002" TYPE="REFERENCE">Agnarsdottir 2002</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Goff-1997" TYPE="REFERENCE">Goff 1997</LINK>; <LINK REF="REF-Olesen-2004a" TYPE="REFERENCE">Olesen 2004a</LINK>). An association with autoimmune diseases (<LINK REF="REF-Bohr-1996" TYPE="REFERENCE">Bohr 1996</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Kitchen-2002" TYPE="REFERENCE">Kitchen 2002</LINK>), and the use of NSAIDs is also common in both lymphocytic colitis and collagenous colitis (<LINK REF="REF-Bohr-1996" TYPE="REFERENCE">Bohr 1996</LINK>; <LINK REF="REF-Chande-2005" TYPE="REFERENCE">Chande 2005</LINK>; <LINK REF="REF-Goff-1997" TYPE="REFERENCE">Goff 1997</LINK>; <LINK REF="REF-Kitchen-2002" TYPE="REFERENCE">Kitchen 2002</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Riddell-1992" TYPE="REFERENCE">Riddell 1992</LINK>; <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>).</P>
<P>Despite sharing certain epidemiologic features, lymphocytic colitis and collagenous colitis have important pathologic differences. The presence of a thickened subepithelial collagen band is the key diagnostic feature found in collagenous colitis. A marked increase in the number of intraepithelial lymphocytes is required to diagnose lymphocytic colitis. Treatments aimed at decreasing the thickness of the collagen band may not necessarily influence the number of intraepithelial lymphocytes. However, most medications used to treat collagenous colitis have anti-inflammatory activities and consequently might be effective at reducing the number of mucosal inflammatory cells in patients with lymphocytic colitis. In fact, some studies of collagenous colitis treatment with follow-up histology have shown a decrease in the number of inflammatory cells, findings which could potentially be translated to patients with lymphocytic colitis (<LINK REF="REF-Baert-2002" TYPE="REFERENCE">Baert 2002</LINK>; <LINK REF="REF-Bonderup-2003" TYPE="REFERENCE">Bonderup 2003</LINK>; <LINK REF="STD-Fine-1999" TYPE="STUDY">Fine 1999</LINK>; <LINK REF="REF-Miehlke-2002" TYPE="REFERENCE">Miehlke 2002</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-07-12 07:38:20 -0400" MODIFIED_BY="John K MacDonald">
<IMPLICATIONS_PRACTICE MODIFIED="2017-07-12 07:38:15 -0400" MODIFIED_BY="John K MacDonald">
<P>Low quality evidence suggests that budesonide may be an effective therapy for the treatment of lymphocytic colitis. Low quality evidence also suggests that mesalazine with or without cholestyramine and beclometasone dipropionate may be effective for treatment of lymphocytic colitis. No conclusions can be made regarding bismuth subsalicylate. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-07-12 07:38:20 -0400" MODIFIED_BY="John K MacDonald">
<P>Further large placebo-controlled trials of budesonide are necessary to confirm the suggested benefit and safety of this therapy. Bismuth subsalicylate, which has less potential for toxicity than budesonide, also warrants further study. The efficacy and safety of mesalazine with or without cholestyramine, and beclometasone dipropionate need to be investigated in a large placebo-controlled study. Other treatments that have been suggested to be beneficial in uncontrolled studies and case series should also be considered for randomized placebo controlled trials.</P>
<P>There are no established definitions for clinical or histological remission in lymphocytic colitis. As a result, the authors of each individual study must determine what they believe to be appropriate endpoints of therapy. Although these endpoints may be similar between studies, important differences may render it inappropriate to compare outcomes between trials. In addition, the clinical relevance of these arbitrary definitions is uncertain. If standardized definitions of clinical and histological remission can be established, the outcomes of these trials would be more applicable to clinical practice.</P>
<P>Most randomized trials in lymphocytic colitis and collagenous colitis deal with short-term outcomes (generally 6 to 8 weeks, with a maximum of 12 months). Both lymphocytic colitis and collagenous colitis are chronic diseases, and longer-term outcomes are important. Once standardized definitions of clinical and histological remission are established, trials with long-term follow-up are warranted to study the effectiveness of both establishing and maintaining remission, as well as to determine the potential for adverse effects with prolonged treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-07-12 07:38:25 -0400" MODIFIED_BY="John K MacDonald">
<P>Partial funding for the Cochrane IBD Group (April 1, 2016 - March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC). </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-07-12 07:38:40 -0400" MODIFIED_BY="John K MacDonald">
<P>Nilesh Chande: Dr Chande has received fees for consultancy from AbbVie, Janssen, Takeda, and Ferring, and fees for lectures from AbbVie, Actavis and Janssen. All of these financial activities are outside the submitted work. </P>
<P>Noor Al Yatama: None known</P>
<P>Tania Bhanji: None known</P>
<P>Tran M Nguyen: None known</P>
<P>John WD McDonald: None known</P>
<P>John K MacDonald: None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF MODIFIED="2017-07-12 07:38:34 -0400" MODIFIED_BY="John K MacDonald"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-11-14 13:29:41 +0000" MODIFIED_BY="John MacDonald">
<STUDIES MODIFIED="2017-07-12 08:08:24 -0400" MODIFIED_BY="John K MacDonald">
<INCLUDED_STUDIES MODIFIED="2017-02-12 18:41:24 -0500" MODIFIED_BY="Noor  Al Yatama">
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-2007" MODIFIED="2016-08-03 16:35:00 -0400" MODIFIED_BY="Claire E Parker" NAME="Calabrese 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-08-03 16:35:00 -0400" MODIFIED_BY="Claire E Parker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese C, Fabbri A, Areni A, Zahlane D, Scialpi C, Di Febo G</AU>
<TI>Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>6</NO>
<PG>809-14</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:35:00 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:34:09 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fine-1999" MODIFIED="2016-08-08 15:19:36 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Fine 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-08-08 15:19:36 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fine K, Ogunji F, Lee E, Lafon G, Tanzi M</AU>
<TI>Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>116</VL>
<NO>4 Part 2</NO>
<PG>A880</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:19:36 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3194413"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:35:14 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Latella-2010" MODIFIED="2016-08-03 16:35:47 -0400" MODIFIED_BY="Claire E Parker" NAME="Latella 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-08-03 16:35:47 -0400" MODIFIED_BY="Claire E Parker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Latella G, Angelucci E, Tsolaki A, Saltarelli P, Necozione S, Frieri G</AU>
<TI>Beclometasone dipropionate and mesalazine are equally effective in the treatment of lymphocytic colitis</TI>
<SO>Digestive and Liver Diseases</SO>
<YR>2010</YR>
<VL>42</VL>
<PG>S87</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:35:47 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290080"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:35:29 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke-2009" MODIFIED="2016-08-25 08:56:28 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Miehlke 2009" YEAR="2007">
<REFERENCE MODIFIED="2016-08-03 16:36:24 -0400" MODIFIED_BY="Claire E Parker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Bethke B, Wonschik S, Kuhlisch E, Beckmann R, et al</AU>
<TI>Budesonide in lymphocytic colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>4 Suppl 2</NO>
<PG>A131-2</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:36:24 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3194420"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-25 08:56:28 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>Miehlke S, Madisch A, Karimi D, Wonschik S, Beckmann R, Kuhlisch E, et al</AU>
<TI>MON-G-338. Budesonide for treatment of lymphocytic colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>October 29, 2007</YR>
<CY>Paris, France</CY>
<IDENTIFIERS MODIFIED="2016-08-03 16:36:31 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3194421"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-03 16:36:35 -0400" MODIFIED_BY="Claire E Parker" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Madisch A, Karimi D, Wonschik S, Kuhlisch E, Beckmann R, et al</AU>
<TI>Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>7</NO>
<PG>2092-100</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:36:35 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:36:17 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194418"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardi-2009" MODIFIED="2016-08-03 16:37:05 -0400" MODIFIED_BY="Claire E Parker" NAME="Pardi 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-08-03 16:37:05 -0400" MODIFIED_BY="Claire E Parker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ</AU>
<TI>A randomized, double-blind, placebo-controlled trial of budesonide for the treatment of active lymphocytic colitis</TI>
<SO>Gastroenterology</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>5 Suppl 1</NO>
<PG>A519-20</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:37:05 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290082"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:36:50 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194423"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-07-12 08:08:24 -0400" MODIFIED_BY="John K MacDonald">
<STUDY DATA_SOURCE="PUB" ID="STD-Bauma-2015" MODIFIED="2017-05-18 15:34:42 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Bauma 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-08-16 11:32:01 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouma G, Munch A</AU>
<TI>Microscopic colitis</TI>
<SO>Digestive Diseases</SO>
<YR>2015</YR>
<VL>33</VL>
<NO>2</NO>
<PG>208-14</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:20:49 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:34:42 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentile-2015" MODIFIED="2017-05-18 15:35:25 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Gentile 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-08-08 15:24:13 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentile N, Abdalla A, Khanna S, Smyrk T, Tremaine W, Faubion W, et al</AU>
<TI>Outcomes of patients with microscopic colitis treated with bismuth subsalicylate</TI>
<SO>Gastroenterology</SO>
<YR>2015</YR>
<VL>1</VL>
<PG>S483</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:21:54 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290084"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:35:25 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jo-2014" MODIFIED="2017-07-12 07:57:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Jo 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-07-12 07:57:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jo KJ, Kim EK, Kim YS</AU>
<TI>Microscopic colitis is a functional gastrointestinal disorder in Asia?</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2014</YR>
<VL>29</VL>
<PG>243</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:25:42 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290158"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:35:35 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loftus-2003" MODIFIED="2017-07-12 08:07:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Loftus 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-07-12 08:07:43 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loftus EV</AU>
<TI>Microscopic colitis: epidemiology and treatment</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>12 Suppl</NO>
<PG>S31-6</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:26:02 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:35:45 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194431"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madisch-2007" MODIFIED="2017-07-12 08:07:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Madisch 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-07-12 08:07:11 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="OTHER">
<AU>Madisch A, Wonschik S, Morgner A, Kuhlisch E, Bethke B, Stolte M, et al</AU>
<TI>Long-term progress of lymphocytic colitis after inducing a clinical remission with budesonide</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>4 Suppl 1</NO>
<PG>A-511</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:26:16 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:35:51 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194433"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miehlke-2013" MODIFIED="2017-05-18 15:35:59 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Miehlke 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-08-16 11:33:00 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke, S</AU>
<TI>Microscopic colitis</TI>
<TO>Mikroskopische kolitis</TO>
<SO>Medizinische Welt</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>4</NO>
<PG>191-4</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:45:56 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:35:59 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194435"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyhlin-2006" MODIFIED="2017-05-18 15:37:26 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Nyhlin 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-08-08 15:45:32 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyhlin N, Bohr J, Eriksson S, Tysk C</AU>
<TI>Systematic review: microscopic colitis</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1525-34</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:39:16 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:37:26 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardi-2002" MODIFIED="2017-06-29 13:50:43 -0400" MODIFIED_BY="John K MacDonald" NAME="Pardi 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-06-29 13:50:43 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ, Sandborn WJ</AU>
<TI>Lymphocytic colitis: Clinical features, treatment, and outcomes</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>11</NO>
<PG>2829-33</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:26:38 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:37:32 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194439"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pardi-2014" MODIFIED="2017-05-18 15:37:11 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Pardi 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-08-08 15:28:33 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS</AU>
<TI>Microscopic colitis</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2014</YR>
<VL>30</VL>
<NO>1</NO>
<PG>55-65</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:28:23 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:37:11 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194441"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parkes-2007" MODIFIED="2017-05-18 15:37:06 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Parkes 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-08-16 11:33:50 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parkes M</AU>
<TI>Microscopic Colitis</TI>
<SO>Medicine</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>5</NO>
<PG>290-1</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:28:44 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290092"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:37:06 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194443"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohatgi-2008" MODIFIED="2017-05-18 15:37:18 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Rohatgi 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-08-08 15:31:02 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohatgi S, Ahuja V</AU>
<TI>A Randomized trial evaluating probiotic preparation Vsl#3 versus oral mesalamine in patients with active microscopic colitis</TI>
<SO>Gastroenterology</SO>
<YR>2008</YR>
<VL>134</VL>
<NO>4 suppl 1</NO>
<PG>A- 712</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:29:00 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:37:18 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194445"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohatgi-2015" MODIFIED="2017-07-04 10:19:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Rohatgi 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-07-04 10:19:51 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohatgi S, Ahuja V, Makharia G, Rai T, Das T, Das P, et al</AU>
<TI>VSL#3 induces and maintains short term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial</TI>
<SO>BMJ Open Gastroenterology</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>1</NO>
<PG>e00018</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:47:26 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290094"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:58 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194447"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-2011" MODIFIED="2017-05-18 15:36:53 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Stewart 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-08-08 15:38:34 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart MJ, Seow CH, Storr MA</AU>
<TI>Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis</TI>
<SO>Clinical Gastroenterology &amp; Hepatology</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>10</NO>
<PG>881-90</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:37:33 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:53 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroehlein-2004" MODIFIED="2017-05-18 15:36:46 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Stroehlein 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-08 15:50:47 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroehlein JR</AU>
<TI>Microscopic Colitis</TI>
<SO>Current Opinion in Gastroenterology</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:50:43 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290096"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:46 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tagkalidis-2002" MODIFIED="2017-05-18 15:36:39 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Tagkalidis 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-08 15:50:34 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tagkalidis P, Bhathal P,Gibson P</AU>
<TI>Microscopic Colitis</TI>
<SO>Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>3</NO>
<PG>236-48</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:50:15 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:39 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194453"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taheri-2011" MODIFIED="2017-05-18 15:36:34 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Taheri 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-08-16 11:34:33 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taheri A, Sadighi A, Nikkhoo B, Farhangi E</AU>
<TI>Evaluation of effects and complications of probiotics in microscopic colitis, a double blind placebo control clinical trial</TI>
<SO>Gastroenterology</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>S-852</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:50:01 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290098"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:34 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194455"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Temmerman-2009" MODIFIED="2017-07-12 08:08:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Temmerman 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-07-12 08:08:24 -0400" MODIFIED_BY="John K MacDonald" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Temmerman F, Baert F</AU>
<TI>Collagenous and lymphocytic colitis: systematic review and update of the literature</TI>
<SO>Digestive Diseases</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>Suppl 1</NO>
<PG>137-45</PG>
<IDENTIFIERS MODIFIED="2016-08-08 15:49:51 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290161"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:39:18 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Triadafilopoulos-2014" MODIFIED="2017-06-09 10:23:29 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Triadafilopoulos 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-09 10:23:29 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Triadafilopoulos, G</AU>
<TI>Glucocorticoid therapy for gastrointestinal diseases</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2014</YR>
<VL>13</VL>
<NO>5</NO>
<PG>563-72</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:39:10 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290100"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:39:04 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194459"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tysk-2005" MODIFIED="2016-08-17 10:58:51 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Tysk 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-08-17 10:58:51 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tysk C, Bohr J, Olesen M, Eriksson S, Jarnerot G</AU>
<TI>Microscopic colitis--more common cause of diarrhea than believed. Biopsies are the only way to diagnosis, drug treatment is effective</TI>
<SO>Lakartidningen</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>32-33</NO>
<PG>2210-4</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:38:57 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:38:51 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194461"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tysk-2009" MODIFIED="2016-08-03 16:38:45 -0400" MODIFIED_BY="Claire E Parker" NAME="Tysk 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-08-03 16:38:40 -0400" MODIFIED_BY="Claire E Parker" NOTES="&lt;p&gt;Tysk, Curt&lt;/p&gt;" NOTES_MODIFIED="2016-08-03 16:38:40 -0400" NOTES_MODIFIED_BY="Claire E Parker" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tysk C</AU>
<TI>Large intestine: Remission of lymphocytic colitis with budesonide</TI>
<SO>Nature Reviews Gastroenterology &amp; Hepatology</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>506-7</PG>
<IDENTIFIERS MODIFIED="2016-08-03 16:38:40 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3194464"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-03 16:38:45 -0400" MODIFIED_BY="Claire E Parker"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194463"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2017-05-18 15:36:16 -0400" MODIFIED_BY="Tran M Nguyen">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00184171" MODIFIED="2017-05-18 15:36:16 -0400" MODIFIED_BY="Tran M Nguyen" NAME="NCT00184171" YEAR="2014">
<REFERENCE MODIFIED="2016-08-08 15:59:36 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00184171</AU>
<TI>Treatment of microscopic colitis (collagenous colitis and lymphocytic colitis) with budesonide, bismuth or fiber</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00184171</SO>
<YR>(accessed 17January 2014)</YR>
<IDENTIFIERS MODIFIED="2016-08-08 15:59:36 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290102"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:16 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194465"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01209208" MODIFIED="2017-05-18 15:36:10 -0400" MODIFIED_BY="Tran M Nguyen" NAME="NCT01209208" YEAR="2014">
<REFERENCE MODIFIED="2016-08-08 15:58:39 -0400" MODIFIED_BY="Tran M Nguyen" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01209208</AU>
<TI>Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with budesonide vs. mesalazine vs. placebo in patients with lymphocytic colitis</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT01209208</SO>
<YR>(accessed 17January 2014)</YR>
<IDENTIFIERS MODIFIED="2016-08-08 15:58:39 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6290103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-18 15:36:10 -0400" MODIFIED_BY="Tran M Nguyen"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3194467"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-07-05 13:08:36 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_REFERENCES MODIFIED="2017-07-05 13:08:36 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Abdo-2001" MODIFIED="2017-07-04 10:23:39 -0400" MODIFIED_BY="John K MacDonald" NAME="Abdo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Abdo AA, Zetler PJ, Halparin LS</AU>
<TI>Familial microscopic colitis</TI>
<SO>Candian Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>5</NO>
<PG>341-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agnarsdottir-2002" MODIFIED="2016-08-08 15:46:36 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Agnarsdottir 2002" TYPE="JOURNAL_ARTICLE">
<AU>Agnarsdottir M, Gunnlaugsson O, Orvar KB, Cariglia N, Birgisson S, Bjornsson S, et al</AU>
<TI>Collagenous and lymphocytic colitis in Iceland</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1122-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baert-1999" MODIFIED="2017-06-29 13:12:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Baert 1999" TYPE="JOURNAL_ARTICLE">
<AU>Baert F, Wouters K, D'Haens G, Hoang P, Naegels S, D'Heygere F, et al</AU>
<TI>Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>3</NO>
<PG>375-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baert-2002" NAME="Baert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, et al</AU>
<TI>Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baert-2004" MODIFIED="2017-06-29 14:23:14 -0400" MODIFIED_BY="John K MacDonald" NAME="Baert 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baert D, Coppens M, Burvenich P, De Cock G, Lagae J, Rasquin K, et al</AU>
<TI>Chronic diarrhoea in non collagenous microscopic colitis: therapeutic effect of cholestyramine</TI>
<SO>Acta Clinica Belgica</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>5</NO>
<PG>258-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barta-2005" MODIFIED="2017-07-04 09:45:40 -0400" MODIFIED_BY="John K MacDonald" NAME="Barta 2005" TYPE="JOURNAL_ARTICLE">
<AU>Barta Z, Mekkel G, Csipo I, Toth L, Szakall S, Szabo G, et al</AU>
<TI>Microscopic colitis: a retrospective study of clinical presentation in 53 patients</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ben-Soussan-2001" MODIFIED="2017-06-29 14:03:25 -0400" MODIFIED_BY="John K MacDonald" NAME="Ben Soussan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ben Soussan E, Savoye G, Lemoine F, Ducastelle P, Colin R</AU>
<TI>Azathioprine as a treatment of refractory lymphocytic colitis</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>4</NO>
<PG>457-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohr-1995" NAME="Bohr 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bohr J, Tysk C, Eriksson S, Jarnerot G</AU>
<TI>Collagenous colitis in Orebro, Sweden, an epidemiological study 1984-1993</TI>
<SO>Gut</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>3</NO>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohr-1996" NAME="Bohr 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bohr J, Tysk C, Eriksson S, Abrahamsson H, Jarnerot G</AU>
<TI>Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>96</NO>
<PG>846-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bohr-1999" MODIFIED="2017-07-04 09:35:52 -0400" MODIFIED_BY="John K MacDonald" NAME="Bohr 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bohr J, Olesen M, Jarnerot G</AU>
<TI>Budesonide and bismuth in microscopic colitis</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<PG>A202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonderup-2003" NAME="Bonderup 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J</AU>
<TI>Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>2</NO>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonderup-2007" NAME="Bonderup 2007" TYPE="OTHER">
<AU>Bonderup O, Hansen J, Teglbjaerg P, Christensen L, Fallingborg J</AU>
<TI>Long-term budesonide treatment of collagenous colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>2007</YR>
<PG>No FP-247</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonner-2000" MODIFIED="2017-07-04 10:01:34 -0400" MODIFIED_BY="John K MacDonald" NAME="Bonner 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bonner GF, Petras RE, Cheong DM, Grewal ID, Breno S, Ruderman WB</AU>
<TI>Short- and long-term follow-up of treatment for lymphocytic and collagenous colitis</TI>
<SO>Inflammatory Bowel Diseases</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>2</NO>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chande-2005" MODIFIED="2016-08-16 11:35:26 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Chande 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chande N, Driman DK, Reynolds RP</AU>
<TI>Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>3</NO>
<PG>343-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chande-2008a" MODIFIED="2017-07-04 14:37:47 -0400" MODIFIED_BY="John K MacDonald" NAME="Chande 2008a" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JWD, MacDonald JK</AU>
<TI>Interventions for treating collagenous colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-07-04 14:37:47 -0400" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2017-07-04 14:37:47 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD003575.pub5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chopra-2006" MODIFIED="2017-07-04 09:43:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Chopra 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chopra A, Pardi D, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, et al</AU>
<TI>Budesonide in the treatment of inflammatory bowel disease: the first of experience in clinical practice</TI>
<SO>Inflammatory Bowel Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Waele-1994" MODIFIED="2017-07-04 12:11:18 -0400" MODIFIED_BY="John K MacDonald" NAME="De Waele 1994" TYPE="JOURNAL_ARTICLE">
<AU>De Waele S, Janssens P, Hoang P, Laka A, Lagneaux G, Lambert M</AU>
<TI>An unusual cause of chronic diarrhea: lymphocytic colitis</TI>
<TO>Une cause inhabituelle de diarrhee chronique: la colite lymphocytaire</TO>
<SO>Acta Clinica Belgica</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>3-4</NO>
<PG>168-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eijsbouts-1995" MODIFIED="2017-07-04 10:06:41 -0400" MODIFIED_BY="John K MacDonald" NAME="Eijsbouts 1995" TYPE="JOURNAL_ARTICLE">
<AU>Eijsbouts AM, Witteman BJ, de Sevaux RG, Fennis JF, van Haelst UJ, Naber AH, et al</AU>
<TI>Undefined malabsorption syndrome with villous atrophy successfully reversed by treatment with cyclosporine</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>8</NO>
<PG>803-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Einarsson-1992" MODIFIED="2017-07-04 09:16:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Einarsson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Einarsson K, Eusufzai S, Johansson U, Lofberg R, Theodorsson E, Veress B</AU>
<TI>Villous atrophy of distal ileum and lymphocytic colitis in a woman with bile acid malabsorption</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>1992</YR>
<VL>4</VL>
<NO>7</NO>
<PG>585-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fekih-2006" MODIFIED="2017-06-29 13:32:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Fekih 2006" TYPE="JOURNAL_ARTICLE">
<AU>Fekih M, Ben Hriz F, Sassi A, Matri S, Filali A, Boubaker J</AU>
<TI>Microscopic colitis. A 20 case series</TI>
<SO>Tunisie Medicale</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>7</NO>
<PG>403-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-1999" MODIFIED="2017-05-30 13:17:27 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Fernandez 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fernández F, Salas A, Forne M, Esteve M, Espinos J, Viver J</AU>
<TI>Incidence of collagenous and lymphocytic colitis: A 5-year population-based study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>2</NO>
<PG>418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-2001" MODIFIED="2017-07-04 09:13:06 -0400" MODIFIED_BY="John K MacDonald" NAME="Fernandez 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez-Banares F, Esteve M, Salas A, Forne TM, Espinos JC, Martin-Comin J, et al</AU>
<TI>Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2001</YR>
<VL>46</VL>
<NO>10</NO>
<PG>2231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-2003" MODIFIED="2017-06-29 13:44:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Fernandez 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fernández F, Salas A, Esteve M, Espinos J, Forne M, Maria J</AU>
<TI>Collagenous and lymphocytic colitis: evaluation of clinical and histological features, response to treatment, and long-term follow-up</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>2</NO>
<PG>340-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fine-1998" MODIFIED="2017-07-04 09:37:58 -0400" MODIFIED_BY="John K MacDonald" NAME="Fine 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fine KD, Lee EL</AU>
<TI>Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>114</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fomegne-2005" MODIFIED="2017-07-04 09:48:34 -0400" MODIFIED_BY="John K MacDonald" NAME="Fomegne 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fomegne G, Gruselle P</AU>
<TI>Microscopic colitis</TI>
<TO>Les colites microscopiques</TO>
<SO>Revue Me&#769;dicale de Bruxelles</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goff-1997" MODIFIED="2016-08-16 11:35:45 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Goff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Goff JS, Barnett JL, Pelke T, Appelman HD</AU>
<TI>Collagenous colitis: histopathology and clinical course</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1997</YR>
<VL>92</VL>
<NO>1</NO>
<PG>57-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-01-17 09:36:43 -0500" MODIFIED_BY="John K MacDonald" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook of Systematic Review of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hilmer-2006" MODIFIED="2017-06-29 12:47:21 -0400" MODIFIED_BY="John K MacDonald" NAME="Hilmer 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hilmer SN, Heap TR, Eckstein RP, Lauer CS, Shenfield GM</AU>
<TI>Microscopic colitis associated with exposure to lansoprazole</TI>
<SO>Medical Journal of Australia</SO>
<YR>2006</YR>
<VL>184</VL>
<NO>4</NO>
<PG>185-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollerweger-2003" MODIFIED="2017-06-29 13:48:55 -0400" MODIFIED_BY="John K MacDonald" NAME="Hollerweger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hollerweger A, Macheiner P, Brunner W</AU>
<TI>Suspicion of microscopic colitis raised by sonographic examination</TI>
<SO>Journal of Clinical Ultrasound</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>4</NO>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jensen-2005" MODIFIED="2017-07-04 10:13:42 -0400" MODIFIED_BY="John K MacDonald" NAME="Jensen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Jensen L, Munck LK</AU>
<TI>Elementary diet reduces diarrhoea associated with microscopic colitis</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1495-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kitchen-2002" MODIFIED="2017-05-30 13:17:53 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Kitchen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kitchen P, Levi J, Domizio P, Talbot I, Forbes A, Price A, et al</AU>
<TI>Microscopic colitis: the tip of the iceberg?</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1199-1204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahmoud-2005" MODIFIED="2017-06-29 14:19:23 -0400" MODIFIED_BY="John K MacDonald" NAME="Mahmoud 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud F, Khalife W, Elaprolu K, Khurana A</AU>
<TI>Microscopic colitis: a report of two cases</TI>
<SO>South Dakota Journal of Medicine</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>4</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mennecier-1999" MODIFIED="2017-07-04 10:27:08 -0400" MODIFIED_BY="John K MacDonald" NAME="Mennecier 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mennecier D, Gros P, Bronstein JA, Thiolet C, Farret O</AU>
<TI>Chronic diarrhea due to lymphocytic colitis treated with piroxicam beta cyclodextrin</TI>
<TO>Diarrhee chronique secondaire a la prise de piroxicam beta-cyclodextrine associee a une colite lymphocytaire</TO>
<SO>Presse Me&#769;dicale</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>14</NO>
<PG>735-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miehlke-2002" NAME="Miehlke 2002" TYPE="JOURNAL_ARTICLE">
<AU>Miehlke S, Heymer P, Bethke B, Bastlein E, Meier E, Bartram HP, et al</AU>
<TI>Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>4</NO>
<PG>978-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miehlke-2007b" NAME="Miehlke 2007b" TYPE="OTHER">
<AU>Miehlke S, Madisch A, Bethke B, Morgner A, Kuhlish E, Henker C, et al</AU>
<TI>Budesonide for maintenance treatment of collagenous colitis - a randomized, double-blind, placebo-controlled trial</TI>
<SO>United European Gastroenterology Week</SO>
<YR>2007</YR>
<PG>No. PS-M-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mullhaupt-1998" MODIFIED="2017-06-29 13:20:53 -0400" MODIFIED_BY="John K MacDonald" NAME="Mullhaupt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mullhaupt B, Guller U, Anabitarte M, Guller R, Fried M</AU>
<TI>Lymphocytic colitis: clinical presentation and long term course</TI>
<SO>Gut</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>5</NO>
<PG>629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Netzer-1997" MODIFIED="2017-07-04 12:07:59 -0400" MODIFIED_BY="John K MacDonald" NAME="Netzer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Netzer P, Levkovits H, Zimmermann A, Halter F</AU>
<TI>Collagen colitis and lymphocytic (microscopic) colitis: different or common origin?</TI>
<TO>Kollagenkolitis und lymphozytare (mikroskopische) Kolitis: differente oder gemeinsame Genese?</TO>
<SO>Zeitschrift fu&#776;r Gastroenterologie</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>9</NO>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olesen-2004a" NAME="Olesen 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Olesen M, Eroksson S, Bohe J, Jarnerot G, Tysk C</AU>
<TI>Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998</TI>
<SO>Gut</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>3</NO>
<PG>346-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olesen-2004b" MODIFIED="2017-06-29 13:10:01 -0400" MODIFIED_BY="John K MacDonald" NAME="Olesen 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Olesen M, Eriksson S, Bohr J, Jarnerot G, Tysk C</AU>
<TI>Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients</TI>
<SO>Gut</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>4</NO>
<PG>536-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pardi-2001" MODIFIED="2017-06-29 14:08:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Pardi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS, Loftus EV Jr, Tremaine WJ, Sandborn WJ</AU>
<TI>Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120</VL>
<NO>6</NO>
<PG>1483-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pardi-2004a" NAME="Pardi 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS, Smyrk TC, Kammer P, Loftus EV Jr, Tremaine WJ, Schleck CD, et al</AU>
<TI>The epidemiology of microscopic colitis (MC): a population-based study in Olmsted County, MN</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>124</VL>
<PG>A124</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pardi-2004b" MODIFIED="2016-08-08 15:51:25 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Pardi 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Pardi DS</AU>
<TI>Microscopic colitis: an update</TI>
<SO>Inflammatory Bowel Disease</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>860-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perk-1999" MODIFIED="2017-07-04 10:29:14 -0400" MODIFIED_BY="John K MacDonald" NAME="Perk 1999" TYPE="JOURNAL_ARTICLE">
<AU>Perk G, Ackerman Z, Cohen P, Eliakim R</AU>
<TI>Lymphocytic colitis: a clue to an infectious trigger</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>1</NO>
<PG>110-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persoz-2001" MODIFIED="2017-07-04 09:59:19 -0400" MODIFIED_BY="John K MacDonald" NAME="Persoz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Persoz CF, Cornella F, Kaeser P, Rochat T</AU>
<TI>Ticlopidine-induced interstitial pulmonary disease: a case report</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1963-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puri-1994" MODIFIED="2017-06-29 13:27:26 -0400" MODIFIED_BY="John K MacDonald" NAME="Puri 1994" TYPE="JOURNAL_ARTICLE">
<AU>Puri AS, Khan EM, Kumar M, Pandey R, Choudhuri G</AU>
<TI>Association of lymphocytic (microscopic) colitis with tropical sprue</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>1</NO>
<PG>105-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raclot-1994" MODIFIED="2017-05-29 14:33:30 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Raclot 1994" TYPE="JOURNAL_ARTICLE">
<AU>Raclot G, Queneau PE, Ottignon Y, Angonin R, Monnot B, Leroy M, et al</AU>
<TI>Incidence of collagenous colitis: a retrospective study in the east of France</TI>
<SO>Gastroenterology</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>4</NO>
<PG>A23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riddell-1992" NAME="Riddell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Riddell RH, Tanaka M, Mazzoleni G</AU>
<TI>Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study</TI>
<SO>Gut</SO>
<YR>1992</YR>
<VL>33</VL>
<NO>5</NO>
<PG>683-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandmeier-2004" MODIFIED="2017-07-04 09:55:54 -0400" MODIFIED_BY="John K MacDonald" NAME="Sandmeier 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sandmeier D, Bouzourene H</AU>
<TI>Microscopic colitis with giant cells: a rare new histopathologic subtype?</TI>
<SO>International Journal of Surgical Pathology</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>1</NO>
<PG>45-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schiller-2004" MODIFIED="2016-08-08 15:57:53 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Schiller 2004" TYPE="JOURNAL_ARTICLE">
<AU>Schiller LR</AU>
<TI>Diagnosis and management of microscopic colitis syndrome</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>Suppl 1</NO>
<PG>S27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2017-07-05 13:08:28 -0400" MODIFIED_BY="John K MacDonald" NAME="Schünemann 2011" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swensson-1999" MODIFIED="2017-06-29 13:17:05 -0400" MODIFIED_BY="John K MacDonald" NAME="Swensson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Swensson O, Stuber E, Nickel T, Sticherling M, Ghohestani RF, Nitsche R, et al</AU>
<TI>Linear IgA disease associated with lymphocytic colitis</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>2</NO>
<PG>317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teahon-1994" MODIFIED="2017-07-04 10:16:51 -0400" MODIFIED_BY="John K MacDonald" NAME="Teahon 1994" TYPE="JOURNAL_ARTICLE">
<AU>Teahon K, Webster AD, Price AB, Weston J, Bjarnason I</AU>
<TI>Studies on the enteropathy associated with primary hypogammaglobulinaemia</TI>
<SO>Gut</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1244-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ung-2002" MODIFIED="2017-07-04 09:10:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Ung 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ung KA, Kilander A, Willen R, Abrahamsson H</AU>
<TI>Role of bile acids in lymphocytic colitis</TI>
<SO>Hepatogastroenterology</SO>
<YR>2002</YR>
<VL>49</VL>
<NO>44</NO>
<PG>432-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Gossum-1998" MODIFIED="2017-07-04 09:52:07 -0400" MODIFIED_BY="John K MacDonald" NAME="Van Gossum 1998" TYPE="JOURNAL_ARTICLE">
<AU>Van Gossum A, Schmit A, Peny MO</AU>
<TI>Oral budesonide for lymphocytic colitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>2</NO>
<PG>270</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varghese-2002" MODIFIED="2017-07-04 12:13:13 -0400" MODIFIED_BY="John K MacDonald" NAME="Varghese 2002" TYPE="JOURNAL_ARTICLE">
<AU>Varghese L, Galandiuk S, Tremaine WJ, Burgart LJ</AU>
<TI>Lymphocytic colitis treated with proctocolectomy and ileal J-pouch-anal anastomosis: report of a case</TI>
<SO>Diseases of the Colon and Rectum</SO>
<YR>2002</YR>
<VL>45</VL>
<NO>1</NO>
<PG>123-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vennamaneni-2001" MODIFIED="2017-06-29 14:12:15 -0400" MODIFIED_BY="John K MacDonald" NAME="Vennamaneni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vennamaneni SR, Bonner GF</AU>
<TI>Use of azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>9</NO>
<PG>2798-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1999" MODIFIED="2017-06-29 13:54:46 -0400" MODIFIED_BY="John K MacDonald" NAME="Wang 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wang N, Dumont J, Achkar E, Easley K, Petras R, Goldblum J</AU>
<TI>Colonic epithelial lymphocytosis without a thickened subepithelial collagen table: A clinicopathologic study of 40 cases supporting a heterogeneous entity</TI>
<SO>American Journal of Surgical Pathology</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1068</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weidenhiller-2005" MODIFIED="2017-06-29 12:43:29 -0400" MODIFIED_BY="John K MacDonald" NAME="Weidenhiller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Weidenhiller M, Muller S, Schwab D, Hahn EG, Raithel M, Winterkamp S</AU>
<TI>Microscopic (collagenous and lymphocytic) colitis triggered by food allergy</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>2</NO>
<PG>312-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiedermann-2007" MODIFIED="2017-07-04 09:40:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Wiedermann 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wiedermann CJ, Zelger A</AU>
<TI>Lymphocytic colitis in a patient with psoriasis responsive to budesonide</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>4</NO>
<PG>538-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yusuf-1999" MODIFIED="2017-07-04 12:16:11 -0400" MODIFIED_BY="John K MacDonald" NAME="Yusuf 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yusuf TE, Soemijarsih M, Arpaia A, Goldberg SL, Sottile VM</AU>
<TI>Chronic microscopic enterocolitis with severe hypokalemia responding to subtotal colectomy</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>3</NO>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zins-1995" MODIFIED="2016-08-08 15:57:11 -0400" MODIFIED_BY="Tran M Nguyen" NAME="Zins 1995" TYPE="JOURNAL_ARTICLE">
<AU>Zins BJ, Sandborn WJ, Tremaine WJ</AU>
<TI>Collagenous and lymphocytic colitis: subject review and therapeutic alternatives</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>90</VL>
<NO>9</NO>
<PG>1394-400</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-06-27 13:57:32 -0400" MODIFIED_BY="John K MacDonald">
<REFERENCE ID="REF-Chande-2007" MODIFIED="2017-06-27 13:57:24 -0400" MODIFIED_BY="John K MacDonald" NAME="Chande 2007" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating lymphocytic colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-07-21 13:43:09 -0400" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2015-07-21 13:43:09 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD006096.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chande-2008b" MODIFIED="2017-06-27 13:57:32 -0400" MODIFIED_BY="John K MacDonald" NAME="Chande 2008b" TYPE="COCHRANE_REVIEW">
<AU>Chande N, McDonald JW, MacDonald JK</AU>
<TI>Interventions for treating lymphocytic colitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-07-21 13:43:48 -0400" MODIFIED_BY="John K MacDonald"><IDENTIFIER MODIFIED="2015-07-21 13:43:48 -0400" MODIFIED_BY="John K MacDonald" TYPE="DOI" VALUE="10.1002/14651858.CD006096.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2017-06-27 13:58:10 -0400" MODIFIED_BY="John K MacDonald"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-07-12 08:20:23 -0400" MODIFIED_BY="John K MacDonald">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-07-12 08:20:23 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-07-12 07:38:34 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Calabrese-2007">
<CHAR_METHODS MODIFIED="2017-05-18 15:28:56 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized, unblinded, open-label study. N=41 with lymphocytic colitis (and 23 with collagenous colitis). Duration of the study was 6 months. Patients underwent a colonoscopy pre-treatment. Twenty patients also underwent a colonoscopy at the end of 6 months.Randomization was performed with a computer generated list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-12 07:38:34 -0400" MODIFIED_BY="John K MacDonald">
<P>Clinical: Chronic or recurrent non-bloody diarrhea<BR/>Histological: Increased chronic inflammatory infiltrate (plasma cells, lymphocytes, eosinophils) in the lamina propria; increased number of intraepithelial lymphocytes, damage to surface epithelium, with flattening of epithelial cells or epithelial loss or both and detachment and minimal crypt architecture distortion. More than 20 intraepithelial lymphocytes per 100 epithelial cells in the absence of a thickened subepithelial collagen layer (&lt; 10 um) was also required to diagnose lymphocytic colitis. Patients with a clear correlation between symptoms and assumption of drugs (e.g. NSAIDS, ticlopidine, PPI) were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-11-17 13:29:30 -0500" MODIFIED_BY="Tran M Nguyen">
<P>Mesalazine 800 mg po tid (n=20) vs. mesalazine 800 mg po tid + cholestyramine 4 g po od (n=21) for 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-11-17 13:29:27 -0500" MODIFIED_BY="Tran M Nguyen">
<P>Clinical: Complete response was complete resolution of diarrhea. Partial response was improvement but not resolution of diarrhea<BR/>Histological: Normalization of histologic pattern at the end of 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-09 10:18:11 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Biopsies were performed in a blinded fashion by a single pathologist</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-12 08:20:23 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Fine-1999">
<CHAR_METHODS MODIFIED="2016-08-25 09:03:46 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized, double-blind, placebo-controlled. Duration of study was 8 weeks<BR/>N=5. Each patient underwent 48-hour stool collection before treatment and on the last 2 days of treatment. Stool weight and consistency were assessed based on standardized criteria. All patients underwent flexible sigmoidoscopy with standardized biopsy protocol pre- and post-treatment. Randomization was by pulling pieces of paper out of a sealed box.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-12 08:20:23 -0400" MODIFIED_BY="John K MacDonald">
<P>Clinical: 8 weeks of non-bloody watery diarrhea (without steatorhea) and normal endoscopic appearance of the colonic mucosa.<BR/>Histological (including involvement of the distal colon): excess mononuclear inflammatory cells in the lamina propria and surface epithelium without significant neutrophilia or eosinophilic inflammation, numerous crypt abscesses, or granuloma; and no other evidence of Crohn's disease. For the histological outcome analysis, a histopathology score from 0 to 10 was based on the following parameters: surface epithelium assessed for micro-ulceration, cell flattening, and mucin depletion (scored: 0 - normal, 1 - moderate, 2 - severe); crypts (scored: 0 - normal, 1 - distorted architecture or cryptitis with neutrophils, 2 - containing crypt abscesses); lamina propria cellularity (scored: 0 - normal, 1 - focally increased with neutrophils, mononuclear inflammatory cells, or both, 2 - diffusely increased with neutrophils, mononuclear inflammatory cells, or both); number of intraepithelial lymphocytes within surface epithelium (scored 0 - normal, 1 - moderately increased, 2 - significantly increased); number of intraepithelial lymphocytes within crypt epithelium (scored 0 - normal, 1 - moderately increased, 2 - significantly increased).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 15:33:48 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Bismuth subsalicylate (9 262 mg chewable tablets daily in 3 divided doses) versus placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-09 10:22:22 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Clinical: improvement of diarrhea to passage of 2 or less formed or semi formed stools/day.<BR/>Histological: improvement of histopathology score by at least 50%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-09 10:18:17 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients were not to take antibiotics or anti-inflammatory agents for minimum 6 weeks, and not to take antidiarrheals for minimum 2 weeks prior to the beginning of the study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-12 07:38:50 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Latella-2010">
<CHAR_METHODS MODIFIED="2017-07-12 07:38:49 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized, unblinded, open-label study. N=46 with lymphocytic colitis. Duration of study was 8 weeks, with a 6 and 12 month follow-up. Patients were treated with either beclometasone dipropionate or mesalazine</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-12 07:38:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Patients with clinical and histologically confirmed lymphocytic colitis</P>
<P>Clinical criteria: &gt;3 watery/loose stools per day on average per week, history of diarrhea &gt;4 weeks</P>
<P>Histological criteria: complete colonoscopy with colonic biopsies within the last 4 weeks before randomization and a histologically confirmed diagnosis of active lymphocytic colitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-12 07:38:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Beclometasone dipropionate 5 mg/day (n=18) vs beclometasone dipropionate 10 mg/day (n=13) vs mesalazine 2.4 g/day (n=15) for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-18 15:28:50 -0400" MODIFIED_BY="Tran M Nguyen">
<P>The primary outcome was clinical remission at 8 weeks.Clinical remission was pre-defined as no more than 3 soft or solid stools per day during the last week of treatment. Clinical relapse at 6 and 12 months, was pre-defined as greater than 3 stools per day on more than 4 consecutive days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-09 10:22:14 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Additional information provided by the lead author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen" STUDY_ID="STD-Miehlke-2009">
<CHAR_METHODS MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized, double-blind, placebo-controlled. Duration of study was 6 weeks. Open label budesonide was offered to non responders for a further 6 weeks. Patients underwent a colonoscopy including histology at baseline and 6 weeks. Randomization was performed with a computer generated list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients with lymphocytic colitis and chronic diarrhea.<BR/>Clinical: more than 3 watery/loose stools per day on average for at least 4 weeks<BR/>Histological: The intraepithelial lymphocytes had to be greater than 20/100 epithelial cells, with inflammation of the lamina propria<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Budesonide 9 mg/day (n = 21) or placebo (n = 21) for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen">
<P>The primary outcome was clinical remission at week 6. Clinical remission was pre-defined as no more than 3 non-watery stools per day. Secondary outcomes included histological remission or response and quality of life (SF-36). Histological remission was defined as a reduction in the number of IEL &lt;20 IEL /100 epithelial cells plus a reduction in lamina propria inflammation. Histological response was defined as &gt;20 IEL/100 epithelial cells but reduction of more than 50% compared to baseline or reduction in lamina propria inflammation or both. Clinical remission at 3 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-18 15:33:35 -0400" MODIFIED_BY="Tran M Nguyen"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-12 07:38:53 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pardi-2009">
<CHAR_METHODS MODIFIED="2017-07-12 07:38:52 -0400" MODIFIED_BY="John K MacDonald">
<P>Randomized, double-blind, placebo controlled study (N = 15)</P>
<P>A stool specimen and blood sample was taken from each participant at the start of the study</P>
<P>Patients took either budesonide (n = 11) or placebo (n = 4) for 8 weeks</P>
<P>At the end of treatment, patients had stool collection and sigmoidoscopy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-09 10:24:19 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients (&gt;18 years) with diarrhea - defined as greater than 4 bowel movements per day and greater than "mild" - and currently on no treatment or despite active treatment. Lymphocytic colitis was confirmed histologically within one year of enrolment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-07-12 07:38:53 -0400" MODIFIED_BY="John K MacDonald">
<P>Budesonide (9 mg/day) compared to placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-07-12 07:38:53 -0400" MODIFIED_BY="John K MacDonald">
<P>The primary outcome measure was satisfactory control of diarrhea during at least three of the last four weeks. The secondary outcome measures were 1) histologic improvement in post treatment colon biopsies compared to baseline biopsies and 2) side effects and time (in days) to recurrence of diarrhea after discontinuation of study drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-23 08:29:33 -0400" MODIFIED_BY="John K MacDonald">
<P>Additional information provided by the lead author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-07-12 07:39:02 -0400" MODIFIED_BY="John K MacDonald" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:53 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Bauma-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:53 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:54 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Gentile-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:54 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:54 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Jo-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:54 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Loftus-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Madisch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Miehlke-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Nyhlin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pardi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Pardi-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Parkes-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Rohatgi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:56 -0400" MODIFIED_BY="John K MacDonald">
<P>Abstract only, no sufficient details</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Rohatgi-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald">
<P>No outcome specific to lymphocytic colitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Stewart-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Stroehlein-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tagkalidis-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:38:57 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-12 07:39:02 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Taheri-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-12 07:39:02 -0400" MODIFIED_BY="John K MacDonald">
<P>This study assessed probiotics compared to placebo</P>
<P>The abstract did not report on clinical symptoms or histology</P>
<P>Authors reported mean defecation results without standard deviations</P>
<P>We tried contacting the authors to get the actual values, but we were unsuccessful in obtaining further data </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-05 11:24:55 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Temmerman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-05 11:24:55 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-05 11:24:54 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Triadafilopoulos-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-05 11:24:54 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-05 11:24:52 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tysk-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-05 11:24:52 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized control trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-07-05 11:24:50 -0400" MODIFIED_BY="John K MacDonald" STUDY_ID="STD-Tysk-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-07-05 11:24:50 -0400" MODIFIED_BY="John K MacDonald">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen" STUDY_ID="STD-NCT00184171">
<CHAR_STUDY_NAME MODIFIED="2017-05-18 15:27:56 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Treatment of microscopic colitis (collagenous colitis and lymphocytic colitis) with budesonide, bismuth or fiber</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-05-18 15:27:56 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized, open-label, active control, parallel group efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients aged &gt; 17 years</P>
<P>Inclusion criteria: microscopic colitis verified with biopsies from the colon</P>
<P>Symptoms to such an extent that treatment is indicated</P>
<P>Informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients assigned to budesonide (9 mg/day) or bismuth and fiber for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Primary outcome: stool frequency and consistency<BR/>Secondary outcome: histological findings in biopsies from colon</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-05-18 15:28:02 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Start date: November 2001<BR/>Estimated study completion date: April 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Study chair: Per G Farup, PhD, Norwegian University of Science and Technology</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-05-18 15:27:45 -0400" MODIFIED_BY="Tran M Nguyen">
<P>ClinicalTrials.gov identifier: NCT00184171</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-05-18 15:27:38 -0400" MODIFIED_BY="Tran M Nguyen" STUDY_ID="STD-NCT01209208">
<CHAR_STUDY_NAME MODIFIED="2017-05-18 15:27:37 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with budesonide vs. mesalazine vs. placebo in patients with lymphocytic colitis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-05-18 15:27:37 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Randomized, double-blind, double-dummy, parallel group efficacy study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-18 15:27:37 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Patients aged 18 to 90 years</P>
<P>Inclusion Criteria: symptoms and signs of indication of lymphocytic colitis</P>
<P>Signed informed consent</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 15:27:37 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Budesonide (9 mg/day), mesalazine (3 g/day) or placebo for 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-18 15:27:38 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Primary outcome: rate of clinical remission at 8 weeks</P>
<P>Secondary outcome: proportion of patients with histological improvement at 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-05-18 15:27:38 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Start date: May 2010<BR/>Estimated study completion date: April 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-05-18 15:27:38 -0400" MODIFIED_BY="Tran M Nguyen">
<P>Principal Investigator: Professor Stephan Miehlke, Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-05-18 15:27:38 -0400" MODIFIED_BY="Tran M Nguyen">
<P>ClinicalTrials.gov identifier: NCT01209208</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-06-09 10:24:14 -0400" MODIFIED_BY="Tran M Nguyen">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-05-29 13:48:30 -0400" MODIFIED_BY="Tran M Nguyen" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:10 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Randomization was performed with a computer generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:15 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Randomization was performed by pulling pieces of paper out of a sealed box</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-29 13:48:30 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>Computer generated randomization sequence </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:05:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>Computer generated randomization sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:33 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-05-29 13:53:28 -0400" MODIFIED_BY="Tran M Nguyen" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-18 15:33:27 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="UNKNOWN" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Allocation concealment not described </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:16 -0400" MODIFIED_BY="John K MacDonald" RESULT="UNKNOWN" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P> Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-29 13:53:28 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>Centralized randomization scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:05:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>Centralized sequence concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:34 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>Sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-06-09 10:24:14 -0400" MODIFIED_BY="Tran M Nguyen" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-20 19:59:21 -0500" MODIFIED_BY="John K MacDonald" RESULT="NO" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>Open-labeled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-09 10:24:14 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>Double blind, identical coloured and flavoured placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-29 13:46:52 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="NO" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>Open label study </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-20 20:05:41 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>Placebo and budesonide were administered in identical capsules. Histological samples were examined by a blinded pathologist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-06-09 10:18:22 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="UNKNOWN" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>Identical placebo was not available from the sponsor at the time of the study. All research personnel including the pathologist were blinded to treatment assignment. Patients did not know treatment assignment unless they discovered what budesonide was supposed to look like. The authors did not formally assess whether patients knew which treatment they received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-05-30 13:06:58 -0400" MODIFIED_BY="Tran M Nguyen" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 08:29:13 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>No dropouts were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-30 13:06:58 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>One patient dropped out of the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-05-29 13:47:46 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>No patients dropped out </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-20 20:05:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>Patient withdrawals and missing outcome data were reported and evenly distributed across treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 08:29:36 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>There were no drop outs and no missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-05-29 13:47:20 -0400" MODIFIED_BY="Tran M Nguyen" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 19:46:15 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:17 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-29 13:47:20 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>All expected outcomes were reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:05:45 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:06:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>All expected outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-05-29 13:47:35 -0400" MODIFIED_BY="Tran M Nguyen" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:14 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Calabrese-2007">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:29:18 -0400" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Fine-1999">
<DESCRIPTION>
<P>The study appears to be free of other potential sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-29 13:47:35 -0400" MODIFIED_BY="Tran M Nguyen" RESULT="YES" STUDY_ID="STD-Latella-2010">
<DESCRIPTION>
<P>The study appears to be free of other potential sources of bias </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:05:46 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Miehlke-2009">
<DESCRIPTION>
<P>The study appears to be free of other potential sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-20 20:06:04 -0500" MODIFIED_BY="John K MacDonald" RESULT="YES" STUDY_ID="STD-Pardi-2009">
<DESCRIPTION>
<P>The study appears to be free of other potential sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-18 12:38:34 -0500" MODIFIED_BY="John K MacDonald" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-01-18 12:38:34 -0500" MODIFIED_BY="John K MacDonald" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-07-12 08:18:29 -0400" MODIFIED_BY="John K MacDonald">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-07-12 07:39:09 -0400" MODIFIED_BY="John K MacDonald" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-04-02 14:27:19 -0400" MODIFIED_BY="John K MacDonald">Bismuth subsalicylate versus placebo for treating lymphocytic colitis</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Bismuth subsalicylate versus placebo for treating lymphocytic colitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with active lymphocytic colitis<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> bismuth subsalicylate versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>bismuth vs placebo</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 5.25 </B>
<BR/>(0.94 to 1.90)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>5<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological response</P>
</TD>
<TD>
<P>
<B>500 per 1000<SUP>1</SUP>
</B>
</P>
</TD>
<TD>
<P>
<B>665 per 1000</B>
</P>
<P>
<B>(135 to 3300)</B>
</P>
</TD>
<TD>
<P>
<B>RR 1.33</B>
</P>
<P>(0.27 to 6.6)</P>
</TD>
<TD>
<P>5</P>
<P>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk estimates come from control arm of meta-analysis, based on included trials.<BR/>
<SUP>2</SUP> Downgraded one level due to unclear risk of bias for allocation concealment.<BR/>
<SUP>3</SUP> Downgraded two levels due to very sparse data (3 events).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-07-12 07:39:34 -0400" MODIFIED_BY="John K MacDonald" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-06-09 10:21:22 -0400" MODIFIED_BY="Tran M Nguyen">Budesonide versus mesalazine for treating lymphocytic colitis</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Budesonide versus mesalazine for treating lymphocytic colitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with active lymphocytic colitis<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> budesonide versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>control</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>budesonide versus placebo</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Clinical response</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>440 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>893 per 1000</B>
<BR/>(550 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.03 </B>
<BR/>(1.25 to 3.33)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>57<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861; </P>
<P>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Histological response</P>
</TD>
<TD>
<P>
<B>313</B> <B>per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>
<B>763 per 1000</B>
<BR/>(353 to 1000)</P>
</TD>
<TD>
<P>
<B>RR 2.44</B>
</P>
<P>(1.13 to 5.28)</P>
</TD>
<TD>
<P>39<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861; </P>
<P>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Adverse events</P>
</TD>
<TD>
<P>
<B>143 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD>
<P>96 per 1000</P>
<P>(17 to 513)</P>
</TD>
<TD>
<P>RR 0.67</P>
<P>(0.12 to 3.59)</P>
</TD>
<TD>
<P>42<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861; </P>
<P>
<B>low</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk estimates come from control arm of meta-analysis, based on included trials.<BR/>
<SUP>2</SUP> Downgraded one level due to unclear risk of bias for blinding or participants and personnel<BR/>
<SUP>3</SUP> Downgraded one level due to sparse data (39 events).<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data (23 events).<BR/>
<SUP>5</SUP> Downgraded two levels due to very sparse data (5 events).<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2017-07-12 08:18:29 -0400" MODIFIED_BY="John K MacDonald" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-04-02 14:29:27 -0400" MODIFIED_BY="John K MacDonald">Mesalazine versus mesalazine + cholestyramine for treating lymphocytic colitis</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Mesalazine versus mesalazine + cholestyramine for treating lymphocytic colitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with maintenance of remission in lymphocytic colitis<BR/>
<B>Settings: </B>outpatient<BR/>
<B>Intervention:</B> Mesalazine versus mesalazine + cholestyramine<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>mesalazine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>mesalazine plus cholestyramine</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical response </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>857 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>849 per 1000</P>
<P>(660 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>RR 0.99<BR/>(0.77 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>41<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low <SUP>,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Histological response</B>
</P>
</TD>
<TD>
<P>857 per 1000</P>
</TD>
<TD>
<P>849 of 1000</P>
<P>(660 to 1000)</P>
</TD>
<TD>
<P>RR 0.99<BR/>(0.77 to 1.28)</P>
</TD>
<TD>
<P>41<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low <SUP>,2,3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk estimates come from control arm of meta-analysis, based on included trials.<BR/>
<SUP>2</SUP> Downgraded one level due to high risk of bias (no blinding) and unclear allocation concealment <BR/>
<SUP>3</SUP> Downgraded one level due to sparse data (35 events)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2017-07-12 07:39:59 -0400" MODIFIED_BY="John K MacDonald" NO="4" READONLY="YES">
<TITLE MODIFIED="2014-04-02 14:30:59 -0400" MODIFIED_BY="John K MacDonald">Beclometasone dipropionate versus mesalazine for treating lymphocytic colitis</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Beclometasone dipropionate versus mesalazine for treating lymphocytic colitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Patients with active or quiescent lymphocytic colitis<BR/>
<B>Settings: </B>outpatient <BR/>
<B>Intervention:</B> Beclometasone dipropionate versus mesalazine<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Mesalazine</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>beclometasone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Clinical response at 8 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>867 per 1000<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>841 per 1000</P>
<P>(650 to 1075)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
</P>
<P>(0.75 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>46<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
<P>low<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Maintenance of clinical response at 12 weeks</P>
</TD>
<TD>
<P>200 of 1000<SUP>1</SUP>
</P>
</TD>
<TD>
<P>258 per 1000</P>
<P>(80 to 836)</P>
</TD>
<TD>
<P>RR 1.29</P>
<P>(0.40 to 4.18)</P>
</TD>
<TD>
<P>46<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
</P>
<P>very low<SUP>2,4</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control group risk estimates come from control arm of meta-analysis, based on included trials.<BR/>
<SUP>2</SUP> Downgraded one level due to high risk of bias (no blinding) .<BR/>
<SUP>3</SUP> Downgraded one level due to sparse data (39 events)<BR/>
<SUP>4</SUP> Downgraded two levels due to very sparse data (11 events)<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-07-04 13:00:43 -0400" MODIFIED_BY="John K MacDonald">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-07-04 13:00:43 -0400" MODIFIED_BY="John K MacDonald" NO="1">
<TITLE>Non-randomized studies of therapies for lymphocytic colitis</TITLE>
<TABLE COLS="2" ROWS="16">
<TR>
<TH>
<P>Therapy</P>
</TH>
<TH>
<P>References</P>
</TH>
</TR>
<TR>
<TD>
<P>Antiallergic therapy</P>
</TD>
<TD>
<P>
<LINK REF="REF-Weidenhiller-2005" TYPE="REFERENCE">Weidenhiller 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Antibiotics</P>
</TD>
<TD>
<P>
<LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Hilmer-2006" TYPE="REFERENCE">Hilmer 2006</LINK>; <LINK REF="REF-Mullhaupt-1998" TYPE="REFERENCE">Mullhaupt 1998</LINK>; <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="REF-Puri-1994" TYPE="REFERENCE">Puri 1994</LINK>; <LINK REF="REF-Swensson-1999" TYPE="REFERENCE">Swensson 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Antidiarrheal agents</P>
</TD>
<TD>
<P>
<LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Fekih-2006" TYPE="REFERENCE">Fekih 2006</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Hilmer-2006" TYPE="REFERENCE">Hilmer 2006</LINK>; <LINK REF="REF-Hollerweger-2003" TYPE="REFERENCE">Hollerweger 2003</LINK>; <LINK REF="REF-Mullhaupt-1998" TYPE="REFERENCE">Mullhaupt 1998</LINK>; <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Azathioprine/6-mercaptopurine</P>
</TD>
<TD>
<P>
<LINK REF="REF-Ben-Soussan-2001" TYPE="REFERENCE">Ben Soussan 2001</LINK>; <LINK REF="REF-Pardi-2001" TYPE="REFERENCE">Pardi 2001</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Vennamaneni-2001" TYPE="REFERENCE">Vennamaneni 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bile acid binding agents</P>
</TD>
<TD>
<P>
<LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Baert-2004" TYPE="REFERENCE">Baert 2004</LINK>; <LINK REF="REF-Einarsson-1992" TYPE="REFERENCE">Einarsson 1992</LINK>; <LINK REF="REF-Fernandez-2001" TYPE="REFERENCE">Fernandez 2001</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Mahmoud-2005" TYPE="REFERENCE">Mahmoud 2005</LINK>; <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Ung-2002" TYPE="REFERENCE">Ung 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bismuth subsalicylate</P>
</TD>
<TD>
<P>
<LINK REF="REF-Bohr-1999" TYPE="REFERENCE">Bohr 1999</LINK>; <LINK REF="REF-Fine-1998" TYPE="REFERENCE">Fine 1998</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Budesonide</P>
</TD>
<TD>
<P>
<LINK REF="REF-Barta-2005" TYPE="REFERENCE">Barta 2005</LINK>; <LINK REF="REF-Chopra-2006" TYPE="REFERENCE">Chopra 2006</LINK>; <LINK REF="REF-Fomegne-2005" TYPE="REFERENCE">Fomegne 2005</LINK>; <LINK REF="REF-Hollerweger-2003" TYPE="REFERENCE">Hollerweger 2003</LINK>; <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="REF-Van-Gossum-1998" TYPE="REFERENCE">Van Gossum 1998</LINK>; <LINK REF="REF-Wiedermann-2007" TYPE="REFERENCE">Wiedermann 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Bulking agents</P>
</TD>
<TD>
<P>
<LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Corticosteroids (traditional)</P>
</TD>
<TD>
<P>
<LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Bonner-2000" TYPE="REFERENCE">Bonner 2000</LINK>; <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Kitchen-2002" TYPE="REFERENCE">Kitchen 2002</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Persoz-2001" TYPE="REFERENCE">Persoz 2001</LINK>; <LINK REF="REF-Sandmeier-2004" TYPE="REFERENCE">Sandmeier 2004</LINK>; <LINK REF="REF-Swensson-1999" TYPE="REFERENCE">Swensson 1999</LINK>; <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cyclosporine</P>
</TD>
<TD>
<P>
<LINK REF="REF-Eijsbouts-1995" TYPE="REFERENCE">Eijsbouts 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Dietary modification/ or elemental diet (check)</P>
</TD>
<TD>
<P>
<LINK REF="REF-Fekih-2006" TYPE="REFERENCE">Fekih 2006</LINK>; <LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Jensen-2005" TYPE="REFERENCE">Jensen 2005</LINK>; <LINK REF="REF-Teahon-1994" TYPE="REFERENCE">Teahon 1994</LINK>; <LINK REF="REF-Weidenhiller-2005" TYPE="REFERENCE">Weidenhiller 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Probiotics</P>
</TD>
<TD>
<P>
<LINK REF="STD-Rohatgi-2015" TYPE="STUDY">Rohatgi 2015</LINK>; <LINK REF="STD-Taheri-2011" TYPE="STUDY">Taheri 2011</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Spasmolytics</P>
</TD>
<TD>
<P>
<LINK REF="REF-Mullhaupt-1998" TYPE="REFERENCE">Mullhaupt 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Sulfasalazine/other 5-ASA</P>
</TD>
<TD>
<P>
<LINK REF="REF-Abdo-2001" TYPE="REFERENCE">Abdo 2001</LINK>; <LINK REF="REF-Baert-1999" TYPE="REFERENCE">Baert 1999</LINK>; <LINK REF="REF-Bonner-2000" TYPE="REFERENCE">Bonner 2000</LINK>; <LINK REF="REF-De-Waele-1994" TYPE="REFERENCE">De Waele 1994</LINK>; <LINK REF="REF-Fekih-2006" TYPE="REFERENCE">Fekih 2006</LINK>; <LINK REF="REF-Fernandez-2003" TYPE="REFERENCE">Fernandez 2003</LINK>; <LINK REF="REF-Hollerweger-2003" TYPE="REFERENCE">Hollerweger 2003</LINK>; <LINK REF="REF-Kitchen-2002" TYPE="REFERENCE">Kitchen 2002</LINK>; <LINK REF="REF-Mennecier-1999" TYPE="REFERENCE">Mennecier 1999</LINK>; <LINK REF="REF-Mullhaupt-1998" TYPE="REFERENCE">Mullhaupt 1998</LINK>; <LINK REF="REF-Netzer-1997" TYPE="REFERENCE">Netzer 1997</LINK>;p <LINK REF="REF-Olesen-2004b" TYPE="REFERENCE">Olesen 2004b</LINK>; <LINK REF="STD-Pardi-2002" TYPE="STUDY">Pardi 2002</LINK>; <LINK REF="REF-Perk-1999" TYPE="REFERENCE">Perk 1999</LINK>; <LINK REF="REF-Wang-1999" TYPE="REFERENCE">Wang 1999</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Surgery</P>
</TD>
<TD>
<P>
<LINK REF="REF-Varghese-2002" TYPE="REFERENCE">Varghese 2002</LINK>; <LINK REF="REF-Yusuf-1999" TYPE="REFERENCE">Yusuf 1999</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-07-12 07:40:17 -0400" MODIFIED_BY="John K MacDonald">
<COMPARISON ID="CMP-001" MODIFIED="2017-06-06 12:00:10 -0400" MODIFIED_BY="Tran M Nguyen" NO="1">
<NAME>Bismuth subsalicylate versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-06-06 12:00:10 -0400" MODIFIED_BY="Tran M Nguyen" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="206.88095445061387" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="3" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="67.7278444414418" CI_START="0.4069596519320916" EFFECT_SIZE="5.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8307672536355306" LOG_CI_START="-0.39044864682361685" LOG_EFFECT_SIZE="0.7201593034059569" MODIFIED="2016-11-08 11:05:35 -0500" MODIFIED_BY="Tran M Nguyen" ORDER="2737" O_E="0.0" SE="1.3047532151257388" STUDY_ID="STD-Fine-1999" TOTAL_1="3" TOTAL_2="2" VAR="1.7023809523809523" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-11-08 11:05:35 -0500" MODIFIED_BY="Tran M Nguyen" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="3" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Bismuth</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bismuth</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.606050454188973" CI_START="0.26911356340768905" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.8199418863236337" LOG_CI_START="-0.5700644131070339" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2016-11-08 11:05:35 -0500" MODIFIED_BY="Tran M Nguyen" ORDER="2738" O_E="0.0" SE="0.816496580927726" STUDY_ID="STD-Fine-1999" TOTAL_1="3" TOTAL_2="2" VAR="0.6666666666666667" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-07-12 07:40:17 -0400" MODIFIED_BY="John K MacDonald" NO="2">
<NAME>Budesonide versus placebo</NAME>
<DICH_OUTCOME CHI2="0.6934013405396704" CI_END="3.325079605808898" CI_START="1.245309059811078" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0348837209302326" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5218020472179744" LOG_CI_START="0.09527714766747905" LOG_EFFECT_SIZE="0.30853959744272674" METHOD="MH" MODIFIED="2017-06-28 11:10:48 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.4050102676610948" P_Q="1.0" P_Z="0.0045740031421664645" Q="0.0" RANDOM="NO" SCALE="158.9" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="25" WEIGHT="100.0" Z="2.835597637697298">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9128915260972894" CI_START="1.1122968263569268" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.46432431212697034" LOG_CI_START="0.04622069807964186" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2016-01-07 19:36:17 -0500" MODIFIED_BY="Noor  Al Yatama" ORDER="2739" O_E="0.0" SE="0.2455961325376691" STUDY_ID="STD-Miehlke-2009" TOTAL_1="21" TOTAL_2="21" VAR="0.060317460317460325" WEIGHT="87.20930232558139"/>
<DICH_DATA CI_END="20.057816733882927" CI_START="0.6592512371264418" EFFECT_SIZE="3.6363636363636362" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.3022836588923068" LOG_CI_START="-0.1809490465528322" LOG_EFFECT_SIZE="0.5606673061697374" MODIFIED="2011-08-19 09:52:08 -0400" MODIFIED_BY="John K MacDonald" ORDER="6" O_E="0.0" SE="0.8712582332987788" STUDY_ID="STD-Pardi-2009" TOTAL_1="11" TOTAL_2="4" VAR="0.7590909090909093" WEIGHT="12.790697674418603"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010669909976125456" CI_END="5.280865121948801" CI_START="1.1316182122786134" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4445701357466065" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.7227050753579491" LOG_CI_START="0.05369992838238745" LOG_EFFECT_SIZE="0.3882025018701683" METHOD="MH" MODIFIED="2017-05-29 15:54:57 -0400" MODIFIED_BY="Tran M Nguyen" NO="2" P_CHI2="0.9177286413474011" P_Q="1.0" P_Z="0.022929331441654946" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="16" WEIGHT="100.0" Z="2.2746100708300427">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.692381268535298" CI_START="0.9978737385662442" EFFECT_SIZE="2.3833333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.7552939808844208" LOG_CI_START="-9.24406721584496E-4" LOG_EFFECT_SIZE="0.37718478708141817" MODIFIED="2017-05-29 15:54:57 -0400" MODIFIED_BY="Tran M Nguyen" ORDER="2740" O_E="0.0" SE="0.44420642422115797" STUDY_ID="STD-Miehlke-2009" TOTAL_1="15" TOTAL_2="13" VAR="0.19731934731934736" WEIGHT="74.6606334841629"/>
<DICH_DATA CI_END="13.28553431742556" CI_START="0.5186562192656509" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.1233790255466825" LOG_CI_START="-0.285120410062731" LOG_EFFECT_SIZE="0.4191293077419757" MODIFIED="2011-08-04 22:38:12 -0400" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.8273595406616217" STUDY_ID="STD-Pardi-2009" TOTAL_1="8" TOTAL_2="3" VAR="0.6845238095238095" WEIGHT="25.339366515837106"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-12 07:40:17 -0400" MODIFIED_BY="John K MacDonald" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Budesonide</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours budesonide</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.590847863778261" CI_START="0.12377144933586896" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5551970054264799" LOG_CI_START="-0.9073795235378426" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2017-05-30 10:45:34 -0400" MODIFIED_BY="Tran M Nguyen" ORDER="13" O_E="0.0" SE="0.8591246929842244" STUDY_ID="STD-Miehlke-2009" TOTAL_1="21" TOTAL_2="21" VAR="0.7380952380952379" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-07-07 14:38:59 -0400" MODIFIED_BY="John K MacDonald" NO="3">
<NAME>Mesalazine versus mesalazine + cholestyramine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-07 14:38:29 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>5-ASA cholestyramine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA cholest</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-ASA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2780938534919586" CI_START="0.7694292364296744" EFFECT_SIZE="0.9916666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.10656274627705598" LOG_CI_START="-0.11383131558724408" LOG_EFFECT_SIZE="-0.0036342846550940556" MODIFIED="2016-11-08 11:05:35 -0500" MODIFIED_BY="Tran M Nguyen" ORDER="2741" O_E="0.0" SE="0.12946056290729097" STUDY_ID="STD-Calabrese-2007" TOTAL_1="20" TOTAL_2="21" VAR="0.01676003734827264" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.5859895979314365E-31" CI_END="1.2780938534919586" CI_START="0.7694292364296745" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9916666666666668" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.10656274627705598" LOG_CI_START="-0.113831315587244" LOG_EFFECT_SIZE="-0.003634284655094007" METHOD="MH" MODIFIED="2017-07-07 14:38:59 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.9484611347793329" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.06463937343227158">
<NAME>Histological response</NAME>
<GROUP_LABEL_1>5-ASA</GROUP_LABEL_1>
<GROUP_LABEL_2>5-ASA cholestyramine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5-ASA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-ASA cholest</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2780938534919586" CI_START="0.7694292364296744" EFFECT_SIZE="0.9916666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.10656274627705598" LOG_CI_START="-0.11383131558724408" LOG_EFFECT_SIZE="-0.0036342846550940556" MODIFIED="2013-12-21 13:42:38 -0500" MODIFIED_BY="Tania Bhanji" ORDER="13" O_E="0.0" SE="0.12946056290729097" STUDY_ID="STD-Calabrese-2007" TOTAL_1="20" TOTAL_2="21" VAR="0.01676003734827264" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-07-06 13:18:23 -0400" MODIFIED_BY="John K MacDonald" NO="4">
<NAME>Beclometasone dipropionate versus mesalazine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-06 12:24:56 -0400" MODIFIED_BY="John K MacDonald" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.52" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Clinical response at 8 weeks</NAME>
<GROUP_LABEL_1>BD</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.24441541539892" CI_START="0.7525818485572592" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.09496538236371538" LOG_CI_START="-0.12344626059293583" LOG_EFFECT_SIZE="-0.01424043911461023" MODIFIED="2013-12-20 19:15:57 -0500" MODIFIED_BY="Tania Bhanji" ORDER="8" O_E="0.0" SE="0.12829608022780623" STUDY_ID="STD-Latella-2010" TOTAL_1="31" TOTAL_2="15" VAR="0.016459884201819694" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-07-06 13:18:23 -0400" MODIFIED_BY="John K MacDonald" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Maintenance of clinical response at 12 months</NAME>
<GROUP_LABEL_1>BD</GROUP_LABEL_1>
<GROUP_LABEL_2>Mesalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours mesalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BD</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.178299356567485" CI_START="0.3984712965828631" EFFECT_SIZE="1.2903225806451613" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.6209995520272454" LOG_CI_START="-0.39960295703986615" LOG_EFFECT_SIZE="0.1106982974936897" MODIFIED="2014-01-20 12:40:14 -0500" MODIFIED_BY="John K MacDonald" ORDER="14" O_E="0.0" SE="0.5995069658899199" STUDY_ID="STD-Latella-2010" TOTAL_1="31" TOTAL_2="15" VAR="0.3594086021505376" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-11-13 17:24:31 -0500" MODIFIED_BY="John K MacDonald">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-13 17:24:31 -0500" MODIFIED_BY="John K MacDonald" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAKpCAYAAACW16oJAAA+hklEQVR42u3dD6QW+fv4/zdZSZJI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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-07-05 08:07:49 -0400" MODIFIED_BY="John K MacDonald" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASYAAAGwCAIAAACLmV/TAAAUAUlEQVR42u3dv24kRffG8ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-11-08 11:05:35 -0500" MODIFIED_BY="Tran M Nguyen"/>
<APPENDICES MODIFIED="2017-05-18 15:27:24 -0400" MODIFIED_BY="Tran M Nguyen">
<APPENDIX ID="APP-01" MODIFIED="2017-05-18 15:27:24 -0400" MODIFIED_BY="Tran M Nguyen" NO="1">
<TITLE MODIFIED="2016-08-18 09:04:31 -0400" MODIFIED_BY="John K MacDonald">Search Strategies</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-18 15:27:24 -0400" MODIFIED_BY="Tran M Nguyen">
<P>
<B>MEDLINE Search Strategy:</B>
</P>
<P>1. random$.tw.</P>
<P>2. factorial$.tw.</P>
<P>3. (crossover$ or cross over$ or cross-over$).tw.</P>
<P>4. placebo$.tw.</P>
<P>5. single blind.mp.</P>
<P>6. double blind.mp.</P>
<P>7. triple blind.mp.</P>
<P>8. (singl$ adj blind$).tw.</P>
<P>9. (double$ adj blind$).tw.</P>
<P>10. (tripl$ adj blind$).tw.</P>
<P>11. assign$.tw.</P>
<P>12. allocat$.tw.</P>
<P>13. crossover procedure/</P>
<P>14. double blind procedure/</P>
<P>15. single blind procedure/</P>
<P>16. triple blind procedure/</P>
<P>17. randomized controlled trial/</P>
<P>18. or/1-17</P>
<P>19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)</P>
<P>20. 18 not 19</P>
<P>21. lymphocytic colitis.mp. or exp lymphocytic colitis/</P>
<P>22. microscopic colitis.mp or exp microscopic colitis/</P>
<P>23. collagenous colitis.mp or exp collagenous colitis/</P>
<P>24. 21 or 22 or 23</P>
<P>25. 20 and 24</P>
<P>
<B>EMBASE Search Strategy:</B>
</P>
<P>1. random$.tw.</P>
<P>2. factorial$.tw.</P>
<P>3. (crossover$ or cross over$ or cross-over$).tw.</P>
<P>4. placebo$.tw.</P>
<P>5. single blind.mp.</P>
<P>6. double blind.mp.</P>
<P>7. triple blind.mp.</P>
<P>8. (singl$ adj blind$).tw.</P>
<P>9. (double$ adj blind$).tw.</P>
<P>10. (tripl$ adj blind$).tw.</P>
<P>11. assign$.tw.</P>
<P>12. allocat$.tw.</P>
<P>13. crossover procedure/</P>
<P>14. double blind procedure/</P>
<P>15. single blind procedure/</P>
<P>16. triple blind procedure/</P>
<P>17. randomized controlled trial/</P>
<P>18. or/1-17</P>
<P>19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)</P>
<P>20. 18 not 19</P>
<P>21. lymphocytic colitis.mp. or exp lymphocytic colitis/</P>
<P>22. microscopic colitis.mp or exp microscopic colitis/</P>
<P>23. collagenous colitis.mp or exp collagenous colitis/</P>
<P>24. 21 or 22 or 23</P>
<P>25. 20 and 24</P>
<P>
<B>Cochrane Library Search Strategy:</B>
</P>
<P>1. microscopic colitis OR lymphocytic colitis OR collagenous colitis</P>
<P>
<B>Cochrane IBD Specialized Register</B>
</P>
<P>1. microscopic colitis (ab/ti) </P>
<P>2. lymphocytic colitis (ab/ti) </P>
<P>3. collagenous colitis (ab/ti)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2016-11-08 11:05:36 -0500" MODIFIED_BY="Tran M Nguyen">

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 reports of 5 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;27 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;248 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;248 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;333 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;221 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;20 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_9897_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="9897"><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Western Ontario</ORGANISATION><CITY>London</CITY><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>